Cubist Pharmaceuticals (CBST) 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 03, 2014
Document and Entity Information	'	'
Entity Registrant Name	'CUBIST PHARMACEUTICALS INC	'
Entity Central Index Key	'0000912183	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	76,295,299
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$233,691	$91,058
Short-term investments	453,291	487,500
Accounts receivable, net	115,125	123,155
Inventory	68,706	57,663
Deferred tax assets, net	46,877	52,507
Prepaid expenses and other current assets	54,680	58,285
Total current assets	972,370	870,168
Property and equipment, net	182,532	177,544
In-process research and development	237,400	896,400
Goodwill	381,930	381,930
Other intangible assets, net	1,322,382	721,066
Other assets	86,658	98,024
Total assets	3,183,272	3,145,132
Current liabilities:	'	'
Accounts payable	30,169	31,877
Accrued liabilities	167,932	245,078
Short-term deferred revenue	7,123	6,411
Short-term contingent consideration	63,709	20,428
Other current liabilities	5,959	7,034
Total current liabilities	274,892	310,828
Long-term deferred revenue	27,396	31,010
Long-term deferred tax liabilities, net	363,772	357,113
Long-term contingent consideration	103,745	202,894
Long-term debt, net	843,493	817,830
Other long-term liabilities	30,327	31,726
Total liabilities	1,643,625	1,751,401
Commitments and contingencies (Notes B, D, H, J, K and M)	'	'
Stockholders’ equity:	'	'
Preferred stock, non-cumulative; convertible, $.001 par value; authorized 5,000,000 shares; no shares issued and outstanding	0	0
Common stock, $.001 par value; authorized 300,000,000 shares; 76,012,863 and 74,428,087 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	76	74
Additional paid-in capital	1,439,048	1,362,240
Accumulated other comprehensive (loss) income	-1,769	215
Retained earnings	102,292	31,202
Total stockholders’ equity	1,539,647	1,393,731
Total liabilities and stockholders’ equity	$3,183,272	$3,145,132

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, non-cumulative; convertible, par value (in dollars per share)	$0.00	$0.00
Preferred stock, non-cumulative; convertible, authorized shares	5,000,000	5,000,000
Preferred stock, non-cumulative; convertible, shares issued	0	0
Preferred stock, non-cumulative; convertible, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized shares	300,000,000	150,000,000
Common stock, shares issued	76,012,863	74,428,087
Common stock, shares outstanding	76,012,863	74,428,087

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
U.S. product revenues, net	$291,883	$243,596	$797,600	$696,347
International product revenues	16,619	12,987	51,131	40,349
Service revenues	0	3,755	0	11,044
Other revenues	653	5,655	16,055	6,961
Total revenues, net	309,155	265,993	864,786	754,701
Costs and expenses:	'	'	'	'
Cost of product revenues	94,959	60,989	257,113	179,705
Research and development expense	66,032	123,423	291,497	352,822
Contingent consideration expense (income)	2,224	2,641	-55,868	7,280
Selling, general and administrative expense	77,791	73,855	227,510	171,945
Restructuring charges	340	1,029	6,248	1,029
Total costs and expenses	241,346	261,937	726,500	712,781
Operating income	67,809	4,056	138,286	41,920
Other (income) expense, net:	'	'	'	'
Interest income	-276	-624	-970	-2,084
Interest expense	14,664	8,924	43,567	23,358
Other (income) expense	-357	34,871	-344	34,777
Total other (income) expense, net	14,031	43,171	42,253	56,051
Income (loss) before income taxes	53,778	-39,115	96,033	-14,131
Provision (benefit) for income taxes	30,949	-5,220	24,943	-1,566
Net income (loss)	22,829	-33,895	71,090	-12,565
Basic net income (loss) per common share	$0.30	($0.50)	$0.94	($0.19)
Diluted net income (loss) per common share	$0.29	($0.50)	$0.90	($0.19)
Shares used in calculating:	'	'	'	'
Basic net income (loss) per common share	75,834,443	67,841,665	75,400,064	66,122,521
Diluted net income (loss) per common share	85,995,727	67,841,665	85,901,660	66,122,521
Total comprehensive income (loss)	$21,041	($33,351)	$69,106	($12,464)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net income (loss)	$71,090	($12,565)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:	'	'
Loss on extinguishment of convertible debt, including write-off of debt issuance costs	0	12,592
Depreciation and amortization	74,831	25,866
Amortization and accretion of investments	5,281	8,680
Amortization of debt discount and debt issuance costs, excluding write-off of debt issuance costs	29,411	13,382
Deferred income taxes	12,289	-23,068
Stock-based compensation	28,372	24,104
Contingent consideration	-55,868	7,280
Payment of contingent consideration	0	-24,254
Provision for inventory reserves	14,014	4,679
Other non-cash	-4,033	-11,877
Changes in assets and liabilities:	'	'
Accounts receivable	8,028	-12,984
Inventory	-17,344	-13,370
Prepaid expenses and other assets	5,992	1,652
Accounts payable and accrued liabilities	-64,927	-29,669
Deferred revenue and other liabilities	-1,346	1,171
Net cash provided by (used in) operating activities	105,790	-28,381
Cash flows from investing activities:	'	'
Acquisition of business, net of acquired cash	0	-671,729
Acquisition of intangible assets	-4,000	0
Purchase of non-voting preferred stock	0	-25,000
Purchases of property and equipment	-21,070	-11,691
Purchases of investments	-403,277	-736,469
Proceeds from maturities of investments	431,895	1,183,443
Payment for purchase option	0	-20,000
Increase in restricted cash	-2,153	0
Net cash provided by (used in) investing activities	1,395	-281,446
Cash flows from financing activities:	'	'
Payment of contingent consideration	0	-15,746
Issuance of common stock, net	33,057	29,621
Excess tax benefit on stock-based awards	8,705	12,861
Proceeds from issuance of convertible debt	0	800,000
Payment of debt issuance costs	0	-24,731
Proceeds from issuance of warrants	0	121,675
Purchase of convertible bond hedge	0	-179,390
Other	-4,625	0
Net cash provided by financing activities	37,137	744,290
Net increase in cash and cash equivalents	144,322	434,463
Effect of changes in foreign exchange rates on cash balances	-1,689	0
Cash and cash equivalents at beginning of period	91,058	104,041
Cash and cash equivalents at end of period	$233,691	$538,504

BASIS_OF_PRESENTATION_AND_ACCO

BASIS OF PRESENTATION AND ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
BASIS OF PRESENTATION AND ACCOUNTING POLICIES	'
	BASIS OF PRESENTATION AND ACCOUNTING POLICIES
	Basis of Presentation and Consolidation
	The accompanying condensed consolidated financial statements are unaudited and have been prepared by Cubist Pharmaceuticals, Inc. ("we," "our," or "us") in accordance with accounting principles generally accepted in the United States of America (GAAP) and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. The year-end condensed consolidated financial statements were derived from audited financial statements, but certain information and footnote disclosures required by GAAP normally included in our annual consolidated financial statements have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements, which are contained in our Annual Report on Form 10-K for the year ended December 31, 2013 (2013 Form 10-K), filed with the Securities and Exchange Commission (SEC) on February 25, 2014. The condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of our financial position and results of operations. Certain reclassifications have been made to prior year amounts to conform to the current year presentation. Also, included in prepaid expenses and other current assets, and other assets on our condensed consolidated balance sheet are $1.4 million and $0.7 million, respectively, of restricted cash as of September 30, 2014.
	The accompanying condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Our results of operations for the three and nine months ended September 30, 2014, include the effects of our acquisitions of Optimer Pharmaceuticals, Inc. (Optimer), and Trius Therapeutics, Inc. (Trius), which we acquired in October 2013 and September 2013, respectively. In addition, our results of operations for the three and nine months ended September 30, 2013, include the results of Trius from September 11, 2013, the date of acquisition.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires extensive use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. The most significant assumptions are employed in estimates used in determining the values of: inventory; investments; acquisition-date fair value and subsequent fair value estimates used to assess impairment of long-lived assets, including goodwill, in-process research and development (IPR&D) and other intangible assets; accrued clinical research costs; contingent consideration; income taxes; stock-based compensation; product rebate, chargeback and return accruals; as well as in estimates used in accounting for contingencies and revenue recognition. Actual results could differ from these estimates.
	Concentration of Risk
	Our accounts receivable as of September 30, 2014 and December 31, 2013, primarily represent amounts due to us from wholesalers, including AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation. We perform ongoing credit evaluations of our key wholesalers, distributors and other customers, and generally do not require collateral. For the three and nine months ended September 30, 2014 and 2013, we did not have any significant write-offs of accounts receivable, and our days sales outstanding has not significantly changed since December 31, 2013.
		Percentage of Total Accounts Receivable Balance as of
		September 30, 2014		December 31, 2013
	AmerisourceBergen Drug Corporation	17%		18%
	Cardinal Health, Inc.	18%		17%
	McKesson Corporation	22%		18%
		Percentage of Total Net Revenues for the Three Months Ended September 30,				Percentage of Total Net Revenues for the Nine Months Ended September 30,
		2014		2013		2014		2013
	AmerisourceBergen Drug Corporation	18%		18%		17%		19%
	Cardinal Health, Inc.	16%		17%		17%		17%
	McKesson Corporation	21%		18%		19%		18%
	IPR&D
	IPR&D acquired in a business combination is capitalized on our condensed consolidated balance sheets at its acquisition-date fair value, net of any accumulated impairment losses. Until the underlying project is completed, these assets are accounted for as indefinite-lived intangible assets, subject to impairment testing. Once the project is completed, the carrying value of the intangible asset is amortized over its estimated useful life. Post-acquisition research and development expenses related to the acquired IPR&D are expensed as incurred.
	IPR&D is tested for impairment on an annual basis, or more frequently if impairment indicators are present. If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to its revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the fair value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our product candidates, we could incur significant charges in the period in which the impairment occurs. The valuation techniques utilized in performing impairment tests incorporate significant assumptions and judgments to estimate the fair value, and the use of different valuation techniques or different assumptions could result in materially different fair value estimates.
	Revenue Recognition
	Our principal sources of revenue during the periods presented were: (i) product revenues of CUBICIN® (daptomycin for injection), DIFICID® (fidaxomicin) and ENTEREG® (alvimopan) in the United States (U.S.); (ii) revenues derived from sales of CUBICIN and DIFICID by our international distribution partners; (iii) license fees and milestone payments that are derived from collaboration, license and commercialization agreements with other biopharmaceutical companies; and (iv) prior to our acquisition of Optimer, service revenues derived from our co-promotion agreement with Optimer for the promotion and support of DIFICID in the U.S., which was terminated on October 24, 2013, as a result of our acquisition of Optimer. Product revenue amounts exclude sales of DIFICID prior to our acquisition of Optimer. The U.S. Food and Drug Administration (FDA) approved SIVEXTRO® (tedizolid phosphate) in the U.S. on June 20, 2014, for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI). We commercially launched SIVEXTRO in the U.S. at the end of the second quarter of 2014. In all instances, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, and collectibility of the resulting receivable is reasonably assured.
	U.S. Product Revenues, net
	All revenues from product sales are recorded net of applicable provisions and allowances in the same period the related sales are recorded.
	Gross U.S. product revenues were offset by provisions for the three and nine months ended September 30, 2014 and 2013, as follows:
		Three Months Ended September 30,							Nine Months Ended September 30,
		2014				2013			2014			2013
		(in thousands)
	Gross U.S. product revenues	$	350,471			$	277,999		$	954,586		$	796,217
	Provisions offsetting U.S. product revenues:
	Contractual adjustments	(21,443		)		(13,249		)	(63,262		)	(43,281		)
	Governmental rebates	(37,145		)		(21,154		)	(93,724		)	(56,589		)
	Total provisions offsetting product revenues	(58,588		)		(34,403		)	(156,986		)	(99,870		)
	U.S. product revenues, net	$	291,883			$	243,596		$	797,600		$	696,347
	Certain of our product sales qualify for rebates or discounts from standard list pricing due to contractual agreements or government-sponsored programs. Our contractual adjustments include provisions for returns, pricing and early payment discounts extended to our external customers, as well as wholesaler distribution fees, and other commercial rebates. Our governmental rebates represent estimated amounts for government-mandated rebates and discounts relating to federal and state programs, such as Medicaid, the Veterans' Administration and Department of Defense (DoD) programs, the Medicare Part D Coverage Gap Discount Program and certain other qualifying federal and state government programs. Estimates and assumptions for reserves are analyzed quarterly. We reversed approximately $6.0 million and $14.1 million of revenue reserves during the three and nine months ended September 30, 2013, respectively, primarily consisting of Medicaid program rebates as a result of receiving claims information from certain state governments and additional data regarding the usage of CUBICIN by managed care organizations.
	International Product Revenues
	Sales with international distribution partners are based upon contractually predetermined transfer price arrangements. Once our distribution partner sells the product to a third party, we may also be owed an additional payment or royalty. Certain agreements with our distribution partners contain multiple elements in which we have continuing performance obligations. In arrangements for which we determine that the undelivered elements cannot be separated from the delivered elements, payments from distribution partners for product are recorded as deferred revenue and amortized to international product revenues over the remaining performance obligation.
	Basic and Diluted Net Income (Loss) Per Share
	Basic net income (loss) per common share has been computed by dividing net income (loss) by the weighted average number of shares outstanding during the period. Diluted net income (loss) per common share has been computed by dividing diluted net income (loss) by the weighted average diluted number of shares outstanding during the period. Except where the result would be antidilutive to net income, diluted net income per common share has been computed assuming the conversion of obligations and the elimination of the interest expense related to our 2.50% convertible senior notes due 2017 (2017 Notes), 1.125% convertible senior notes due 2018 (2018 Notes), 1.875% convertible senior notes due 2020 (2020 Notes), the exercise of stock options, the exercise of warrants issued in connection with the convertible bond hedge transactions discussed below, and the vesting of restricted stock units (RSUs), as well as their related income tax effects.
	In September 2013, in connection with the issuance of the 2018 Notes and 2020 Notes, we entered into convertible bond hedge transactions. The convertible bond hedges are not considered for purposes of calculating the number of diluted shares outstanding, as their effect would be antidilutive. The convertible bond hedges are generally expected, but not guaranteed, to reduce the potential dilution upon conversion of the 2018 Notes and 2020 Notes. See Note H., "Debt," for additional information.
	The following table sets forth the computation of basic and diluted net income (loss) per common share for the periods presented:
		Three Months Ended September 30,							Nine Months Ended September 30,
		2014				2013			2014			2013
		(in thousands, except share and per share data)
	Net income (loss), basic	$	22,829			$	(33,895	)	$	71,090		$	(12,565	)
	Effect of dilutive securities:
	Interest on 2017 Notes, net of tax	772				—			2,343			—
	Debt issuance costs related to 2017 Notes, net of tax	104				—			315			—
	Debt discount amortization related to 2017 Notes, net of tax	1,100				—			3,265			—
	Net income (loss), diluted	$	24,805			$	(33,895	)	$	77,013		$	(12,565	)
	Shares used in calculating basic net income (loss) per common share	75,834,443				67,841,665			75,400,064			66,122,521
	Effect of dilutive securities:
	Options to purchase shares of common stock and RSUs	2,318,634				—			2,658,833			—
	2017 Notes convertible into shares of common stock	7,842,650				—			7,842,763			—
	Shares used in calculating diluted net income (loss) per common share	85,995,727				67,841,665			85,901,660			66,122,521
	Basic net income (loss) per common share	$	0.3			$	(0.50	)	$	0.94		$	(0.19	)
	Diluted net income (loss) per common share	$	0.29			$	(0.50	)	$	0.9		$	(0.19	)
	Potential common shares excluded from the calculation of diluted net income (loss) per common share, as their inclusion would have been antidilutive, were as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014		2013
	Options to purchase shares of common stock and RSUs	904,954			8,739,777			750,827		8,739,777
	Warrants	9,705,442			9,705,442			9,705,442		9,705,442
2020 Notes convertible into shares of common stock	5,459,311			5,459,311			5,459,311		5,459,311
2018 Notes convertible into shares of common stock	4,246,131			4,246,131			4,246,131		4,246,131
2017 Notes convertible into shares of common stock	—			7,842,943			—		7,842,943
At our annual meeting of shareholders in June 2014, our stockholders approved an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 150.0 million to 300.0 million.
Accumulated Other Comprehensive Income
Accumulated other comprehensive income consists of unrealized gains or losses on available-for-sale securities and foreign currency translation adjustments. Amounts recorded to accumulated other comprehensive income for the three and nine months ended September 30, 2014 and 2013, were not material. Additionally, there were no material reclassifications out of accumulated other comprehensive income for the three and nine months ended September 30, 2014 and 2013.
Recent Accounting Pronouncements
In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. The standard clarifies that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. Additionally, compensation cost should be recognized in the period in which it becomes probable that the performance condition will be achieved. This ASU is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. We elected to adopt this standard in the third quarter of 2014, and the adoption of this ASU did not have a material impact on our consolidated financial statements.
In May 2014, the FASB issued ASU No. 2014-09—Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification 605, Revenue Recognition. This ASU stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This ASU is effective for annual and interim reporting periods beginning on or after December 15, 2016, and early adoption is not permitted. The ASU permits the use of two transition methods, either retrospectively to each prior reporting period presented or as a cumulative-effect adjustment as of the date of adoption. We have not yet selected a transition method, and are currently evaluating the impact of the adoption of this ASU on our consolidated financial statements.

BUSINESS_COMBINATIONS_AND_ACQU

BUSINESS COMBINATIONS AND ACQUISITIONS	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
BUSINESS COMBINATIONS AND ACQUISITIONS	'
	BUSINESS COMBINATIONS AND ACQUISITIONS
	On October 24, 2013, we completed our acquisition of Optimer, then a publicly-held biopharmaceutical company, upon which Optimer became our wholly-owned subsidiary. The transaction provided us with an existing commercialized product, DIFICID. Under the terms of the merger agreement, we purchased 100% of the issued and outstanding shares of Optimer common stock for: (i) $10.75 per share in cash, plus (ii) one transferable contingent value right (CVR) per share, which entitles the holder to receive an additional cash payment of up to $5.00 per CVR upon achievement of certain sales milestones for a maximum, undiscounted potential CVR payout of $253.9 million. The CVRs are listed on the NASDAQ Global Select Market under the symbol "CBSTZ," and this contingent consideration is recorded as a liability and measured at fair value based upon the market price of the CVR on the day of valuation. See Note D., "Fair Value Measurements," for additional information.
	On September 11, 2013, we completed our acquisition of Trius, then a publicly-held biopharmaceutical company, upon which Trius became our wholly-owned subsidiary. The transaction provided us with SIVEXTRO, which at that time was a late-stage product candidate. The FDA approved SIVEXTRO in the U.S. on June 20, 2014, and we commercially launched SIVEXTRO in the U.S. at the end of the second quarter of 2014. Under the terms of the merger agreement, we purchased 100% of the issued and outstanding shares of Trius common stock for: (i) $13.50 per share in cash, plus (ii) one non-transferable CVR per share, which entitles the holder to receive an additional cash payment of up to $2.00 per CVR upon achievement of certain sales milestones for a maximum, undiscounted potential CVR payout of $108.4 million. The CVRs may not be sold, assigned, transferred, pledged, encumbered or disposed of, subject to limited exceptions. Contingent consideration is recorded as a liability and measured at fair value based upon significant unobservable inputs. See Note D., "Fair Value Measurements," for additional information.
	The acquisition-date fair value of the consideration transferred for the Optimer and Trius acquisitions was as follows:
		Total Acquisition-Date Fair Value
		Optimer			Trius
		(in thousands)
	Cash transferred	$	569,452		$	695,710
	Contingent consideration	115,634			4,603
	Total consideration transferred	$	685,086		$	700,313
	The transactions were accounted for as business combinations under the acquisition method of accounting. Accordingly, the tangible and identifiable intangible assets acquired and liabilities assumed were recorded at fair value as of the acquisition dates, with the difference between the acquisition-date fair value of the consideration transferred recorded as goodwill.
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the respective dates of acquisition, as adjusted for measurement period adjustments recorded during the three months ended September 30, 2014:
		Optimer			Trius
		24-Oct-13			11-Sep-13
		(in thousands)
	Cash	$	31,466		$	22,697
	Investments	42,067			39,513
	Inventory	32,000			—
	IPR&D	—			659,000
	DIFICID intangible asset	561,000			—
	Contract intangible asset	36,000			—
	Deferred tax assets	116,422			93,179
	Goodwill	108,360			159,440
	Other assets acquired	15,942			5,522
	Total assets acquired	943,257			979,351
	Deferred tax liabilities	(224,062		)	(248,679		)
	Other liabilities assumed	(34,109		)	(30,359		)
	Total liabilities assumed	(258,171		)	(279,038		)
	Total net assets acquired	$	685,086		$	700,313
	The purchase price allocations were prepared on a preliminary basis and, in the case of Optimer, are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. During the three months ended September 30, 2014, we recorded immaterial measurement period adjustments to both the Trius and Optimer purchase price allocations, and as of September 30, 2014, the measurement period for Trius has closed. Any measurement period adjustments to the Optimer purchase price allocation will be made as soon as practicable but no later than one year from the respective date of acquisition.
	Goodwill is not expected to be deductible for income tax purposes. Goodwill is recorded as an indefinite-lived asset and is not amortized but tested for impairment on an annual basis or when indications of impairment exist.

INVESTMENTS

INVESTMENTS	9 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
INVESTMENTS	'
	INVESTMENTS
	Marketable Securities
	The following table summarizes the amortized cost and estimated fair value of our marketable securities, which are considered to be available-for-sale investments and included in short-term investments on the condensed consolidated balance sheets:
		Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
		(in thousands)
	Balance as of September 30, 2014
	Bank deposits	$	60,200	$	—	$	—		$	60,200
	U.S. Treasury securities	70,181		5		(1		)	70,185
	Corporate and municipal notes	307,919		21		(43		)	307,897
	Total	$	438,300	$	26	$	(44	)	$	438,282
	Balance as of December 31, 2013
	Bank deposits	$	40,000	$	—	$	—		$	40,000
	U.S. Treasury securities	67,648		6		(4		)	67,650
	Corporate and municipal notes	362,561		173		(36		)	362,698
	Total	$	470,209	$	179	$	(40	)	$	470,348
	Certain short-term debt securities with original maturities of less than 90 days are included in cash and cash equivalents on the condensed consolidated balance sheets and are not included in the tables above. In addition, certificates of deposit of $15.0 million and $17.2 million as of September 30, 2014 and December 31, 2013, respectively, were included within short-term investments in the condensed consolidated balance sheets but are excluded from the tables above as they were not deemed to be securities.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	FAIR VALUE MEASUREMENTS
	Recurring Fair Value Measurements
	The following table sets forth our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2014:
		Level 1		Level 2			Level 3			Total
		(in thousands)
	Assets
	Cash and cash equivalents: (1)
	Corporate and municipal notes	$	—	$	1,502		$	—		$	1,502
	Short-term investments: (2)
	Bank deposits	—		60,200			—			60,200
	U.S. Treasury securities	70,185		—			—			70,185
	Corporate and municipal notes	—		307,897			—			307,897
	Total assets	$	70,185	$	369,599		$	—		$	439,784
	Liabilities
	Contingent consideration - Optimer CVRs	$	6,094	$	—		$	—		$	6,094
	Contingent consideration - other	—		—			161,360			161,360
	Total liabilities	$	6,094	$	—		$	161,360		$	167,454
	(1)         Excludes $232.2 million of cash as of September 30, 2014.
	(2)         Excludes certificates of deposit of $15.0 million recorded at cost as of September 30, 2014.
	We did not transfer any assets or liabilities between levels during the three and nine months ended September 30, 2014.
	Marketable Securities
	We classify our U.S. Treasury securities as Level 1 assets under the fair value hierarchy as these assets have been valued using quoted market prices in active markets without any valuation adjustment. We classify our bank deposits and corporate and municipal notes as Level 2 assets under the fair value hierarchy, as these assets have been valued using information obtained through a third-party pricing service at each balance sheet date, using observable market inputs that may include trade information, broker or dealer quotes, bids, offers, or a combination of these data sources.
	Contingent Consideration
	Level 1
	In connection with the acquisition of Optimer, we issued one transferable CVR for each outstanding share of Optimer's common stock. The fair value of the liability relating to the amount payable by us to the holders of the CVRs upon the achievement of certain sales milestones for DIFICID and other specified products was $6.1 million and $68.6 million as of September 30, 2014 and December 31, 2013, respectively. The fair value of the liability is based upon the market price of the security, which is traded in an active market. Changes in the fair value of the liability related to changes in the market price of the security are recognized within the condensed consolidated statements of comprehensive income. The undiscounted amount of contingent consideration that we could pay to the holders of the Optimer CVRs ranges from zero to $253.9 million.
	Level 3
	In connection with the acquisitions of Trius, Adolor Corporation (Adolor) and Calixa Therapeutics Inc. (Calixa), we recorded contingent consideration pertaining to the amounts potentially payable to the former stockholders of each company. Such contingent consideration is measured at fair value and based on significant inputs not observable in the market. The valuation of contingent consideration uses assumptions we believe would be made by a market participant. We assess these estimates on an ongoing basis as additional data impacting the assumptions is obtained. Changes in the fair value of contingent consideration related to updated assumptions and estimates are recognized within the condensed consolidated statements of comprehensive income.
	Contingent consideration may change significantly as development progresses and additional data is obtained that will affect our assumptions regarding probabilities of successful achievement of related milestones used to estimate the fair value of the liability and the timing in which they are expected to be achieved. In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques could result in materially different fair value estimates.
	The following table provides quantitative information associated with the fair value measurement of our Level 3 contingent consideration:
		Fair Value as of September 30, 2014				Unobservable Inputs
		(in thousands)		Valuation technique		Probability of success - range (weighted average)	Periods in which milestones are expected to be achieved		Discount rate
	Trius	$	5,310	Probability-adjusted discounted cash flow		4.0% - 6.5%	2016		8.00%
						-5.80%
	Adolor	46,128		Probability-adjusted discounted cash flow		25.0% - 30.0%	2018 - 2022		5.3% / 13.0%
						-27.00%
	Calixa	109,922		Probability-adjusted discounted cash flow		40.0% - 86.0%	2014 - 2018		5.30%
						-65.00%
	Total	$	161,360
	The significant unobservable inputs used in the fair value measurement of our contingent consideration are the probabilities of successful achievement of development, regulatory and sales milestones, the period in which these milestones are expected to be achieved and a discount rate. Significant increases or decreases in any of the probabilities of success would result in a significantly higher or lower fair value measurement, respectively. Significant increases or decreases in the discount rate and/or the period in which the milestones will be achieved would result in a significantly lower or higher fair value measurement, respectively.
	Trius Therapeutics, Inc.—The fair value of contingent consideration payable by us to the former stockholders of Trius upon the achievement of certain sales milestones of SIVEXTRO and other specified products was estimated to be $5.3 million and $5.0 million as of September 30, 2014 and December 31, 2013, respectively. The change in the fair value of the contingent consideration liability during the three and nine months ended September 30, 2014, is due to the time value of money. The undiscounted amount of contingent consideration that we could pay to the former stockholders of Trius under the merger agreement ranges from zero to $108.4 million. SIVEXTRO is a once daily intravenous and oral oxazolidinone antibiotic treatment for certain serious skin infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
	Adolor Corporation—The fair value of contingent consideration payable by us to the former stockholders of Adolor upon the achievement of certain regulatory milestones, sales milestones or a combination of both, with respect to bevenopran, was estimated to be $46.1 million and $44.2 million as of September 30, 2014 and December 31, 2013, respectively. The change in the fair value of the contingent consideration liability during the three and nine months ended September 30, 2014, is due to the time value of money. The aggregate remaining, undiscounted amount of contingent consideration that we could pay to the former stockholders of Adolor under the merger agreement ranges from zero to $233.8 million. Bevenopran is in development as a potential treatment for opioid-induced constipation (OIC) in patients with chronic, non-cancer pain.
	Calixa Therapeutics Inc.—The fair value of contingent consideration payable by us to the former stockholders of Calixa upon the achievement of certain regulatory and sales milestones with respect to ZERBAXATM (ceftolozane/tazobactam for injection) was estimated to be $109.9 million and $105.6 million as of September 30, 2014 and December 31, 2013, respectively. The change in the fair value of the contingent consideration liability during the three and nine months ended September 30, 2014, is due to the time value of money. The aggregate remaining, undiscounted amount of contingent consideration that we could pay to the former stockholders of Calixa under the merger agreement ranges from zero to $180.0 million. ZERBAXA is in development as a potential treatment for complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
	Changes in the fair value of our Level 3 contingent consideration were as follows:
		Contingent Consideration
		(in thousands)
	Beginning balance as of December 31, 2013	$	154,761
	Contingent consideration expense	6,599
	Ending balance as of September 30, 2014	$	161,360
	Other Fair Value Measurements
	Debt
	We estimate the fair value of our 2020 Notes, 2018 Notes and 2017 Notes (Convertible Senior Notes) by using a quoted market rate in an inactive market, which is classified as a Level 2 input. The estimated fair values of the Convertible Senior Notes consisted of the following at:
		September 30, 2014		December 31, 2013
		(in thousands)
	2020 Notes	$	499,235	$	516,843
	2018 Notes	378,452		403,473
	2017 Notes	526,833		550,317
	Total estimated fair value of Convertible Senior Notes	$	1,404,520	$	1,470,633
	See Note H., “Debt,” for additional information.
	Payable to Glaxo
	In connection with the acquisition of Adolor in December 2011, we assumed the obligation to pay Glaxo Group Limited (Glaxo) six annual payments aggregating to $22.5 million as a result of Adolor’s termination of its collaboration agreement with Glaxo in September 2011. The amount payable to Glaxo was recorded at its estimated fair value at the time of acquisition and is allocated between current and non-current liabilities within the condensed consolidated balance sheets based on the contractual payment dates. The fair value estimate utilizes a discount rate, which is classified as a Level 3 input. As of September 30, 2014, the $11.3 million carrying value of the remaining annual payments to Glaxo approximates its fair value. Imputed interest on the amount payable to Glaxo is recorded as interest expense within the condensed consolidated statements of comprehensive income.

INVENTORY

INVENTORY	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
INVENTORY	'
	INVENTORY
	Inventory consisted of the following at:
		September 30, 2014		December 31, 2013
		(in thousands)
	Raw materials	$	31,806	$	17,904
	Work-in-process	19,249		8,104
	Finished goods	17,651		31,655
	Inventory	68,706		57,663
	Included in other assets:
	Raw materials	50,109		57,284
	Work-in-process	—		1,882
	Finished goods	1,737		—
	Total	$	120,552	$	116,829
	Inventory included in other assets within the condensed consolidated balance sheets as of September 30, 2014 and December 31, 2013, represents the amount of acquired inventory held in excess of the amount expected to be sold within one year. In connection with the acquisitions of Optimer and Adolor, we recorded the acquired DIFICID and ENTEREG inventory, respectively, at fair value, which required a step-up adjustment to recognize the inventory at its expected net realizable value.

GOODWILL_IPRD_AND_OTHER_INTANG

GOODWILL, IPR&D AND OTHER INTANGIBLE ASSETS, NET	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
GOODWILL, IPR&D AND OTHER INTANGIBLE ASSETS, NET	'
	GOODWILL, IPR&D AND OTHER INTANGIBLE ASSETS, NET
	Goodwill
	Our goodwill balance as of September 30, 2014, remained unchanged from the balance as of December 31, 2013. As of September 30, 2014, there were no accumulated impairment losses. Goodwill has been assigned to our single reporting unit, which is the single operating segment by which the chief operating decision maker manages the business. See Note L., “Segment Information,” for additional information.
	IPR&D
	The carrying value of our IPR&D assets consisted of the following at:
		September 30, 2014				December 31, 2013
		(in thousands)
	Development and potential commercialization of:
	SIVEXTRO	$	—			$	659,000
	Bevenopran	43,400				43,400
	ZERBAXA for HABP and VABP	174,000				174,000
	ZERBAXA for cUTI and cIAI	20,000				20,000
	Total IPR&D	$	237,400			$	896,400
	Upon FDA approval of SIVEXTRO in the U.S. in June 2014, we reclassified the IPR&D related to SIVEXTRO to acquired technology rights within other intangible assets.
	Other Intangible Assets
	Other intangible assets, net consisted of the following at:
			September 30, 2014				December 31, 2013
			(in thousands)
	Patents		$	2,627			$	2,627
	Acquired technology rights		1,451,800				788,800
	Other intangible assets, gross		1,454,427				791,427
	Less:	accumulated amortization — patents	(2,539		)		(2,493		)
		accumulated amortization — acquired technology rights	(129,506		)		(67,868		)
	Other intangible assets, net		$	1,322,382			$	721,066
	Amortization expense, which is primarily included within cost of product revenues, was $28.0 million and $5.2 million for the three months ended September 30, 2014 and 2013, respectively, and $61.7 million and $15.4 million for the nine months ended September 30, 2014 and 2013, respectively. The increase in amortization expense was primarily due to amortization of the DIFICID and SIVEXTRO intangible assets associated with our acquisitions of Optimer and Trius in October and September 2013, respectively, which are included in acquired technology rights. The increase in acquired technology rights is due to the reclassification of SIVEXTRO from IPR&D, as discussed above. Additionally, during the nine months ended September 30, 2014, we capitalized a $4.0 million milestone payment to Dong-A ST Co., Ltd in connection with the FDA approval of SIVEXTRO, which was included in acquired technology rights.
	The estimated aggregate amortization of intangible assets as of September 30, 2014, for each of the five succeeding years and thereafter is as follows:
		(in thousands)
	Remainder of 2014	$	28,002
	2015	112,004
	2016	110,724
	2017	109,484
	2018	109,484
	2019 and thereafter	852,684
	Total	$	1,322,382

ACCRUED_LIABILITIES

ACCRUED LIABILITIES	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
ACCRUED LIABILITIES	'
	ACCRUED LIABILITIES
	Accrued liabilities consisted of the following at:
		September 30, 2014		December 31, 2013
		(in thousands)
	Accrued royalties	$	48,727	$	83,591
	Accrued clinical research costs	36,269		44,830
	Accrued bonus	16,313		24,540
	Accrued restructuring	2,684		19,753
	Accrued Medicaid, Medicare and commercial rebates	26,930		18,595
	Accrued benefits and incentive compensation	14,041		18,183
	Other accrued costs	22,968		35,586
	Accrued liabilities	$	167,932	$	245,078
	In the three months ended September 30, 2014, we reversed $14.3 million of accrued clinical research costs, primarily related to a change in estimate based on updated cost estimates received from our CRO on our ZERBAXA cUTI and cIAI Phase 3 clinical trials. The process of accruing clinical research costs includes a number of estimates and assumptions as discussed in Item 7 of Part II under the heading "Critical Accounting Policies and Estimates" in our 2013 Form 10-K filed with the SEC on February 25, 2014.

DEBT

DEBT	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
DEBT	'
	DEBT
	Convertible Senior Notes
	Long-term debt, net is comprised of our Convertible Senior Notes, as follows:
		September 30, 2014			December 31, 2013
		(in thousands)
	2020 Convertible Senior Notes
	Principal amount outstanding	$	450,000		$	450,000
	Unamortized discount	(100,763		)	(111,015		)
	Net carrying amount	349,237			338,985
	2018 Convertible Senior Notes
	Principal amount outstanding	350,000			350,000
	Unamortized discount	(56,312		)	(65,733		)
	Net carrying amount	293,688			284,267
	2017 Convertible Senior Notes
	Principal amount outstanding	228,809			228,822
	Unamortized discount	(28,241		)	(34,244		)
	Net carrying amount	200,568			194,578
	Total Convertible Senior Notes
	Principal amount outstanding	1,028,809			1,028,822
	Unamortized discount	(185,316		)	(210,992		)
	Net carrying amount	$	843,493		$	817,830
	In accordance with accounting guidance for debt with conversion and other options, we separately accounted for the liability and equity components of the Convertible Senior Notes by allocating the proceeds between the liability component and the embedded conversion option, or equity component, due to our ability to settle the Convertible Senior Notes in cash, common stock or a combination of cash and common stock upon conversion, at our option. The allocation was performed in a manner that reflected our non-convertible borrowing rate for similar debt. The equity component of the Convertible Senior Notes was recognized as a debt discount and represents the difference between the proceeds from the issuance of the convertible notes and the fair value of the liability of the Convertible Senior Notes on their respective issuance dates. The debt discount is amortized to interest expense using the effective interest method over the expected life of a similar liability without an equity component.
	2018 Convertible Senior Notes and 2020 Convertible Senior Notes
	In September 2013, we issued $800.0 million aggregate principal amount of convertible senior unsecured notes in two series, with one series consisting of $350.0 million aggregate principal amount of the 2018 Notes, and the other series consisting of $450.0 million aggregate principal amount of the 2020 Notes, resulting in net proceeds to us, after debt issuance costs, of $775.6 million. The 2018 Notes and 2020 Notes are convertible into common stock at an initial conversion rate of 12.1318 shares of common stock per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $82.43 per share of common stock. Holders of the 2018 Notes and 2020 Notes may convert their notes at any time prior to the close of business on the business day immediately before March 1, 2018, or March 1, 2020, respectively, only under the following circumstances: (i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (ii) during the five business day period after any five consecutive trading day period, or the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or (iii) upon the occurrence of specified corporate events.
	The 2018 Notes and 2020 Notes will mature on September 1, 2018 and September 1, 2020, respectively, unless repurchased or converted in accordance with their terms prior to such date. The 2018 Notes and 2020 Notes bear cash interest at an annual rate of 1.125% and 1.875%, respectively, which is payable on March 1st and September 1st of each year, beginning on March 1, 2014. As of September 30, 2014, the “if-converted value” did not exceed the principal amount of the 2018 Notes and 2020 Notes.
	2017 Convertible Senior Notes
	In October 2010, we issued $450.0 million aggregate principal amount of the 2017 Notes, resulting in net proceeds to us, after debt issuance costs, of $436.0 million. In September 2013, holders of $221.2 million aggregate principal amount of the 2017 Notes converted their notes into common stock in privately negotiated transactions. The remaining 2017 Notes are convertible into common stock at an initial conversion rate of 34.2759 shares of common stock per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $29.18 per share of common stock. Holders of the 2017 Notes may convert the 2017 Notes at any time prior to the close of business on the business day immediately preceding May 1, 2017, only under the following circumstances: (i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (ii) during the five business day period after any five consecutive trading day period, or the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or (iii) upon the occurrence of specified corporate events.
	The remaining 2017 Notes will mature on November 1, 2017, unless repurchased or converted in accordance with their terms prior to such date. The 2017 Notes bear cash interest at an annual rate of 2.50%, which is payable on May 1st and November 1st of each year. As of September 30, 2014, the “if-converted value” exceeded the remaining principal amount of the 2017 Notes by $291.5 million.
	Convertible Bond Hedge and Warrant Transactions
	In September 2013, in connection with the issuance of the 2018 Notes and the 2020 Notes, to minimize the impact of potential dilution to our common stock upon conversion of such notes, we entered into convertible bond hedges covering 9,705,442 shares of our common stock. The convertible bond hedges have an exercise price of approximately $82.43 per share and are exercisable when and if the 2018 Notes and 2020 Notes are converted. If upon conversion of the 2018 Notes and 2020 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of our common stock and/or cash with an aggregate value approximately equal to the difference between the price of our common stock at the conversion date and the exercise price, multiplied by the number of shares of our common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges are separate transactions entered into by us and are not part of the terms of the 2018 Notes, 2020 Notes or the warrants described below. Holders of the 2018 Notes, 2020 Notes and warrants will not have any rights with respect to the convertible bond hedges. We paid $179.4 million for these convertible bond hedges and recorded this amount as a reduction to additional paid-in capital, net of tax.
	Concurrently with entering into the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants to acquire, subject to customary adjustments, 9,705,442 shares of our common stock with an exercise price of approximately $96.43 per share, also subject to adjustment. The warrants are exercisable over the 80 trading day period beginning on November 30, 2018, or November 30, 2020, as applicable. The warrants will have a dilutive effect to the extent that the market price per share of our common stock, as measured under the terms of the warrant transactions, exceeds the applicable exercise price of the warrants during the measurement period at the maturity of the warrants. We received $121.7 million for these warrants and recorded this amount to additional paid-in capital.
	Credit Facility
	In November 2012, we entered into a $150.0 million three-year senior secured, syndicated revolving credit facility (the credit facility) with a group of lenders, including Royal Bank of Canada (RBC), as administrative agent. In September 2013, we entered into an amendment to the credit facility. The credit facility was amended to: (i) permit the 2018 Notes, 2020 Notes and the convertible bond hedge and warrant transactions; (ii) adjust the definition of consolidated EBITDA to permit specific acquisitions; (iii) modify certain covenants related to investments, restricted payments and indebtedness; (iv) add additional financial covenants including a senior secured leverage ratio and minimum liquidity requirement; (v) increase the maximum permitted level of our total leverage ratio; and (vi) allow for the option to increase the credit facility by up to an additional $150.0 million, subject to pro forma compliance with financial covenants under the credit facility. In addition, the amendment added a new pricing tier based on our total leverage ratio. As a result, the applicable margin ranges from 2.25% to 3.00% for the Eurodollar rate and 1.25% to 2.00% for the base rate based on our total leverage ratio. The credit facility, which includes a sublimit for letters of credit, is for general corporate purposes. There were no outstanding borrowings under the credit facility as of September 30, 2014, or December 31, 2013.

EMPLOYEE_STOCK_BENEFIT_PLANS

EMPLOYEE STOCK BENEFIT PLANS	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
EMPLOYEE STOCK BENEFIT PLANS	'
	EMPLOYEE STOCK BENEFIT PLANS
	Summary of Stock-Based Compensation Plans
	In June 2014, our stockholders approved our 2014 Omnibus Incentive Plan (2014 OIP), which replaced our 2012 Equity Incentive Plan (2012 EIP). The 2014 OIP is the only existing equity compensation plan from which we are authorized to make equity-based awards to our employees, directors, consultants and advisors. Under the 2014 OIP, we reserved 4,200,000 new shares of common stock plus 1,637,295 shares that remained available for grant under the 2012 EIP as of the effective date of the 2014 OIP for equity-based awards to our employees, officers, directors, consultants and advisors in the form of stock options, RSUs, performance-based restricted stock units (PRSUs), stock grants and stock appreciation rights. In addition, the number of shares of common stock available for grant under the 2014 OIP includes the number of shares of common stock subject to stock options and RSUs that were granted and outstanding under the 2012 EIP, 2010 Equity Incentive Plan (2010 EIP), the Amended and Restated 2002 Directors’ Equity Incentive Plan and the Amended and Restated 2000 Equity Incentive Plan (2000 EIP) as of the effective date of the 2014 OIP, and that may become available for grant upon the forfeiture, cancellation, expiration or termination of those awards. As of September 30, 2014, there were 5,347,920 shares remaining available for grant under the 2014 OIP. Additionally in June 2014, our stockholders approved our 2014 Employee Stock Purchase Plan (2014 ESPP). The maximum aggregate number of shares of our common stock that may be purchased under the 2014 ESPP is 2,000,000 shares, subject to adjustment as provided for in the plan.
	Summary of Stock-Based Compensation Expense
	Stock-based compensation expense recorded in the condensed consolidated statements of comprehensive income for the three and nine months ended September 30, 2014 and 2013, is as follows:
		Three Months Ended September 30,							Nine Months Ended September 30,
		2014				2013			2014			2013
		(in thousands)
	Stock-based compensation expense allocation:
	Cost of product revenues	$	341			$	120		$	610		$	374
	Research and development expense	3,116				2,816			9,835			8,583
	Selling, general and administrative expense	5,947				5,029			17,927			15,147
	Total stock-based compensation expense	9,404				7,965			28,372			24,104
	Income tax effect	(3,069		)		(2,993		)	(9,619		)	(9,058		)
	After-tax effect of stock-based compensation expense	$	6,335			$	4,972		$	18,753		$	15,046
	General Option Information
	A summary of option activity for the nine months ended September 30, 2014, is as follows:
		Number of shares				Weighted Average Exercise Price
	Outstanding as of December 31, 2013	7,478,169				$	31.61
	Granted	759,820				$	72.36
	Exercised	(1,106,320		)		$	25.47
	Canceled	(196,027		)		$	42.41
	Outstanding as of September 30, 2014	6,935,642				$	36.75
	Vested and exercisable as of September 30, 2014	4,673,781				$	29.7
	Weighted average grant-date fair value of options granted during the period	$	19.33
	RSU Information
	A summary of RSU activity, including PRSUs, for the nine months ended September 30, 2014, is as follows:
		Number of Shares			Weighted Average Grant Date Fair Value
	Nonvested as of December 31, 2013	882,272			$	40.97
	Granted	766,260			$	70.37
	Vested	(291,563	)		$	38
	Forfeited	(80,569	)		$	52.53
	Nonvested as of September 30, 2014	1,276,400			$	58.57

RESTRUCTURING

RESTRUCTURING	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
RESTRUCTURING	'
	RESTRUCTURING
	The following table summarizes the activity within the restructuring liability included in accrued liabilities and other long-term liabilities within the condensed consolidated balance sheets:
		Employee-Related Severance			Lease Restructuring			Total
		(in thousands)
	Balance at December 31, 2013	$	19,173		$	4,495		$	23,668
	Restructuring charges	5,315			933			6,248
	Cash payments made	(23,299		)	(2,250		)	(25,549		)
	Balance at September 30, 2014	$	1,189		$	3,178		$	4,367
	In connection with our acquisitions of Trius and Optimer, we committed to a restructuring program in the fourth quarter of 2013, which included severance benefits primarily related to former Optimer employees and restructuring Optimer's lease obligations related to its New Jersey and California facilities. Additionally, in the first quarter of 2014, we committed to a restructuring program for severance benefits related to former Trius employees. The restructuring liability associated with all severance benefits is expected to be paid during 2014.
	In connection with our acquisition of Optimer, we vacated Optimer's leased premises, as we do not intend to occupy or utilize this space for our operations. As a result, we recorded a lease restructuring liability, which represents the lease obligations associated with the vacated space in both the Optimer New Jersey and California facilities, net of expected sublease income. The restructuring liability associated with the leases is expected to be paid over the lease terms ending in 2018 and 2022 for the New Jersey and California facilities, respectively. Any future changes to our estimate of the liability will be recorded as additional restructuring expense or income.

INCOME_TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	INCOME TAXES
	The following tables reconcile the federal statutory tax rate to the effective tax rates and the related impact to the provision (benefit) for income taxes for the three and nine months ended September 30, 2014 and 2013:
		Three Months Ended September 30, 2014					Three Months Ended September 30, 2013
		Amount			Rate		Amount			Rate
		(in thousands, except for percentages)
	Federal statutory tax rate applied to income before taxes	$	18,822		35	%	$	(13,690	)	35	%
	Differential arising from:
	State	2,425			4.5	%	(928		)	2.4	%
	Non-deductible expenses	3,537			6.6	%	2,036			(5.2	)%
	Domestic manufacturing deduction	—			—	%	(577		)	1.5	%
	Contingent consideration	1,442			2.7	%	1,823			(4.7	)%
	2013 Federal research credit	—			—	%	(6,394		)	16.3	%
	Prior year federal research credits	—			—	%	(360		)	0.9	%
	Transaction costs	—			—	%	2,739			(7.0	)%
	Non-deductible loss on extinguishment of 2017 Notes	—			—	%	9,538			(24.4	)%
	Impact of reserve for uncertain tax positions	88			0.2	%	39			(0.1	)%
	Foreign rate differential	3,989			7.4	%	(90		)	0.2	%
	Valuation allowance - foreign losses	1,252			2.3	%	—			—	%
	Other	(606		)	(1.2	)%	644			(1.6	)%
	Total	$	30,949		57.5	%	$	(5,220	)	13.3	%
		Nine Months Ended September 30, 2014					Nine Months Ended September 30, 2013
		Amount			Rate		Amount			Rate
		(in thousands, except for percentages)
	Federal statutory tax rate applied to income before taxes	$	33,612		35	%	$	(4,946	)	35	%
	Differential arising from:
	State	2,220			2.3	%	(485		)	3.4	%
	Non-deductible expenses	2,669			2.8	%	2,438			(17.3	)%
	Domestic manufacturing deduction	—			—	%	(1,386		)	9.8	%
	Contingent consideration	(20,773		)	(21.6	)%	2,241			(15.8	)%
	2013 Federal research credit	—			—	%	(7,701		)	54.5	%
	Prior year federal research credits	—			—	%	(4,401		)	31.1	%
	Transaction costs	—			—	%	2,739			(19.4	)%
	Non-deductible loss on extinguishment of 2017 Notes	—			—	%	9,538			(67.5	)%
	Impact of reserve for uncertain tax positions	257			0.3	%	(371		)	2.6	%
	Foreign rate differential	5,751			6	%	(110		)	0.8	%
	Valuation allowance - foreign losses	1,836			1.9	%	—			—	%
	Other	(629		)	(0.7	)%	878			(6.1	)%
	Total	$	24,943		26	%	$	(1,566	)	11.1	%
	In the tables above, permanent differences that increase the tax benefit for the three and nine months ended September 30, 2013, are shown as increases to the effective tax rate. Permanent differences that decrease the tax benefit for the three and nine months ended September 30, 2013, are shown as decreases to the effective tax rate.
	The effective tax rate for the nine months ended September 30, 2014, was impacted by non-taxable contingent consideration income recorded during that period related to the change in market value of the Optimer CVRs, which is a discrete adjustment for which no tax expense was recorded. The effective tax for the three and nine months ended September 30, 2013, included $6.8 million and $12.1 million, respectively, in benefits from federal research credits. The federal research credit expired at the end of 2013. If the credit is extended, it could have an impact on our effective tax rate in future periods.
	Contingent consideration will fluctuate as a result of any changes in the fair value assumptions based on any additional data received on our SIVEXTRO, ZERBAXA and/or bevenopran programs, as well as based upon the market price of the CVRs issued in connection with our acquisition of Optimer. Any significant contingent consideration expense or income will result in a significantly higher or lower effective tax rate because contingent consideration expense is largely not deductible for tax purposes and contingent consideration income is not taxable.
	Our total uncertain tax positions were $51.6 million and $43.1 million as of September 30, 2014 and December 31, 2013, respectively. The increase in our uncertain tax positions was primarily related to the valuation of intellectual property rights for SIVEXTRO direct sales outside of the U.S., which were transferred to one of our foreign subsidiaries during the three months ended June 30, 2014. Of the total uncertain tax positions as of September 30, 2014, $18.5 million were included in other long-term liabilities within the condensed consolidated balance sheets and $33.1 million were offset against deferred tax assets. Our 2011 and 2012 federal income tax returns are currently under audit by the Internal Revenue Service (IRS). Of the total uncertain tax positions at September 30, 2014, approximately $13.9 million relate to positions on the 2011 and 2012 tax returns. Based on the outcome of the audit, some or all of these positions may be effectively settled in the next 12 months.

SEGMENT_INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
SEGMENT INFORMATION	'
	SEGMENT INFORMATION
	We have one operating segment: the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Our entire business is managed by a single management team, which reports to our Chief Executive Officer. For the three months ended September 30, 2014 and 2013, we generated approximately 94% and 95% of revenues, respectively, within the U.S., and for the nine months ended September 30, 2014 and 2013, we generated approximately 92% and 94% of revenues, within the U.S. As of September 30, 2014 and December 31, 2013, substantially all of our long-lived assets were held within the U.S.

LEGAL_PROCEEDINGS

LEGAL PROCEEDINGS	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
LEGAL PROCEEDINGS	'
	LEGAL PROCEEDINGS
	CUBICIN Patent Inter Partes Review Proceedings
	On October 23, 2014 and October 24, 2014, Agila Specialties Inc. and Mylan Pharmaceuticals Inc. filed seven petitions before the Patent Trial and Appeal Board (the Board) of the U.S. Patent and Trademark Office requesting inter partes reviews of U.S. Patent Nos. 6,468,967 and 6,852,689, which expire on September 24, 2019, and U.S. Patent Nos. 8,058,238 and 8,129,342, which expire on November 28, 2020. On November 3, 2014, Fresenius-Kabi USA LLC (Fresenius) filed two petitions before the Board requesting inter partes reviews of U.S. Patent Nos. 6,468,967 and 6,852,689. Each of these patents is listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) for CUBICIN. The petitions assert that certain claims in the respectively referenced patents are unpatentable and should be canceled.
	While we intend to continue to vigorously defend our patent rights, we cannot predict the outcome of these proceedings. Until these proceedings are finally resolved, the uncertainty of the outcomes may cause our stock price to decline. An adverse result in any of these proceedings, whether appealable or not, would likely cause our stock price to decline. In addition, any final, unappealable adverse result in any of these proceedings would likely have a material adverse effect on the continued commercialization of CUBICIN, our business, results of operations and financial condition, and cause our stock price to decline.
	CUBICIN Patent Infringement Litigation
	In 2012, we filed patent infringement lawsuits in the U.S. District Court for the District of Delaware against Hospira, Inc. (Hospira) in response to certain Paragraph IV Certification Notice Letters from Hospira notifying us that Hospira had submitted an Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) to the FDA seeking approval to market generic versions of CUBICIN. The trial in these related actions was held in the U.S. District Court for the District of Delaware in February 2014. We entered into an agreement with Hospira in July 2014, which we amended in October 2014, under which Hospira has agreed not to launch a daptomycin product in the U.S. before the earlier of: (i) January 9, 2015; or (ii) the court’s decision on the validity and/or infringement of all asserted claims of the relevant patents in these actions.
	In October 2013, we filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Strides, Inc., on behalf of Agila Specialties Private Limited (collectively, Strides), in response to a Paragraph IV Certification Notice Letter from Strides notifying us that Strides had submitted an ANDA to the FDA seeking approval to market a generic version of CUBICIN.
	In July 2014, we filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Fresenius in response to a Paragraph IV Certification Notice Letter from Fresenius notifying us that Fresenius had submitted an ANDA to the FDA seeking approval to market a generic version of CUBICIN.
	We cannot predict the outcome of these CUBICIN patent infringement litigations, and any final, unappealable adverse result in any of these litigations would likely have material adverse effects on our business, results of operations and financial condition.
	Optimer U.S. Governmental Investigations
	We are continuing to cooperate with the investigations by the SEC and the U.S. Department of Justice in their review of potential violations by Optimer of certain applicable laws, which occurred prior to our acquisition of Optimer. The investigations relate to an attempted share grant by Optimer and certain related matters in 2011, including a potentially improper payment to a research laboratory involving an individual associated with the share grant, that may have violated certain applicable laws, including the Foreign Corrupt Practices Act (FCPA). Optimer had already taken remedial steps in response to its internal investigation of these matters; nonetheless, these events could result in lawsuits being filed against us or Optimer and certain of Optimer’s former employees and directors, or certain of our employees. Such persons could also be the subject of criminal or civil enforcement proceedings and we may be required to indemnify such persons for any costs or losses incurred in connection with such proceedings. We cannot predict the ultimate resolution of these matters, whether we or such persons will be charged with violations of applicable civil or criminal laws, or whether the scope of the investigations will be extended to new issues. We also cannot predict what potential penalties or other remedies, if any, the authorities may seek against us, any of our employees, or any of Optimer’s former employees and directors, or what the collateral consequences may be of any such government actions. We do not have any amounts accrued related to potential penalties or other remedies related to these matters as of September 30, 2014, and cannot estimate a reasonably possible range of loss. In the event any such lawsuit is filed or enforcement proceeding is initiated, we could be subject to a variety of risks and uncertainties that could have material adverse effects on our business, results of operations and financial condition.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	SUBSEQUENT EVENTS
	On October 20, 2014, we announced that Michael W. Bonney, Chief Executive Officer of Cubist, plans to retire on December 31, 2014, and has been elected Non-Executive Chairman of the Board of Directors of Cubist effective January 1, 2015. Pursuant to the terms of his separation agreement, we will provide Mr. Bonney with certain termination benefits and payments, including the modification of certain of his equity awards. We are evaluating the financial impact of his separation agreement, and estimate the additional stock-based compensation expense to be recorded in the fourth quarter of 2014 to be approximately $11.0 million.

BASIS_OF_PRESENTATION_AND_ACCO1

BASIS OF PRESENTATION AND ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Consolidation	'
	Basis of Presentation and Consolidation
	The accompanying condensed consolidated financial statements are unaudited and have been prepared by Cubist Pharmaceuticals, Inc. ("we," "our," or "us") in accordance with accounting principles generally accepted in the United States of America (GAAP) and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. The year-end condensed consolidated financial statements were derived from audited financial statements, but certain information and footnote disclosures required by GAAP normally included in our annual consolidated financial statements have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements, which are contained in our Annual Report on Form 10-K for the year ended December 31, 2013 (2013 Form 10-K), filed with the Securities and Exchange Commission (SEC) on February 25, 2014. The condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of our financial position and results of operations. Certain reclassifications have been made to prior year amounts to conform to the current year presentation. Also, included in prepaid expenses and other current assets, and other assets on our condensed consolidated balance sheet are $1.4 million and $0.7 million, respectively, of restricted cash as of September 30, 2014.
	The accompanying condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Our results of operations for the three and nine months ended September 30, 2014, include the effects of our acquisitions of Optimer Pharmaceuticals, Inc. (Optimer), and Trius Therapeutics, Inc. (Trius), which we acquired in October 2013 and September 2013, respectively. In addition, our results of operations for the three and nine months ended September 30, 2013, include the results of Trius from September 11, 2013, the date of acquisition.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires extensive use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. The most significant assumptions are employed in estimates used in determining the values of: inventory; investments; acquisition-date fair value and subsequent fair value estimates used to assess impairment of long-lived assets, including goodwill, in-process research and development (IPR&D) and other intangible assets; accrued clinical research costs; contingent consideration; income taxes; stock-based compensation; product rebate, chargeback and return accruals; as well as in estimates used in accounting for contingencies and revenue recognition. Actual results could differ from these estimates.
Concentration of Risk	'
	Concentration of Risk
	Our accounts receivable as of September 30, 2014 and December 31, 2013, primarily represent amounts due to us from wholesalers, including AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation. We perform ongoing credit evaluations of our key wholesalers, distributors and other customers, and generally do not require collateral. For the three and nine months ended September 30, 2014 and 2013, we did not have any significant write-offs of accounts receivable, and our days sales outstanding has not significantly changed since December 31, 2013.
		Percentage of Total Accounts Receivable Balance as of
		September 30, 2014		December 31, 2013
	AmerisourceBergen Drug Corporation	17%		18%
	Cardinal Health, Inc.	18%		17%
	McKesson Corporation	22%		18%
		Percentage of Total Net Revenues for the Three Months Ended September 30,				Percentage of Total Net Revenues for the Nine Months Ended September 30,
		2014		2013		2014		2013
	AmerisourceBergen Drug Corporation	18%		18%		17%		19%
	Cardinal Health, Inc.	16%		17%		17%		17%
	McKesson Corporation	21%		18%		19%		18%
IPR&D	'
	IPR&D
	IPR&D acquired in a business combination is capitalized on our condensed consolidated balance sheets at its acquisition-date fair value, net of any accumulated impairment losses. Until the underlying project is completed, these assets are accounted for as indefinite-lived intangible assets, subject to impairment testing. Once the project is completed, the carrying value of the intangible asset is amortized over its estimated useful life. Post-acquisition research and development expenses related to the acquired IPR&D are expensed as incurred.
	IPR&D is tested for impairment on an annual basis, or more frequently if impairment indicators are present. If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to its revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the fair value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our product candidates, we could incur significant charges in the period in which the impairment occurs. The valuation techniques utilized in performing impairment tests incorporate significant assumptions and judgments to estimate the fair value, and the use of different valuation techniques or different assumptions could result in materially different fair value estimates.
Revenue Recognition	'
	Revenue Recognition
	Our principal sources of revenue during the periods presented were: (i) product revenues of CUBICIN® (daptomycin for injection), DIFICID® (fidaxomicin) and ENTEREG® (alvimopan) in the United States (U.S.); (ii) revenues derived from sales of CUBICIN and DIFICID by our international distribution partners; (iii) license fees and milestone payments that are derived from collaboration, license and commercialization agreements with other biopharmaceutical companies; and (iv) prior to our acquisition of Optimer, service revenues derived from our co-promotion agreement with Optimer for the promotion and support of DIFICID in the U.S., which was terminated on October 24, 2013, as a result of our acquisition of Optimer. Product revenue amounts exclude sales of DIFICID prior to our acquisition of Optimer. The U.S. Food and Drug Administration (FDA) approved SIVEXTRO® (tedizolid phosphate) in the U.S. on June 20, 2014, for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI). We commercially launched SIVEXTRO in the U.S. at the end of the second quarter of 2014. In all instances, revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, and collectibility of the resulting receivable is reasonably assured.
	U.S. Product Revenues, net
	All revenues from product sales are recorded net of applicable provisions and allowances in the same period the related sales are recorded.
	Gross U.S. product revenues were offset by provisions for the three and nine months ended September 30, 2014 and 2013, as follows:
		Three Months Ended September 30,							Nine Months Ended September 30,
		2014				2013			2014			2013
		(in thousands)
	Gross U.S. product revenues	$	350,471			$	277,999		$	954,586		$	796,217
	Provisions offsetting U.S. product revenues:
	Contractual adjustments	(21,443		)		(13,249		)	(63,262		)	(43,281		)
	Governmental rebates	(37,145		)		(21,154		)	(93,724		)	(56,589		)
	Total provisions offsetting product revenues	(58,588		)		(34,403		)	(156,986		)	(99,870		)
	U.S. product revenues, net	$	291,883			$	243,596		$	797,600		$	696,347
	Certain of our product sales qualify for rebates or discounts from standard list pricing due to contractual agreements or government-sponsored programs. Our contractual adjustments include provisions for returns, pricing and early payment discounts extended to our external customers, as well as wholesaler distribution fees, and other commercial rebates. Our governmental rebates represent estimated amounts for government-mandated rebates and discounts relating to federal and state programs, such as Medicaid, the Veterans' Administration and Department of Defense (DoD) programs, the Medicare Part D Coverage Gap Discount Program and certain other qualifying federal and state government programs. Estimates and assumptions for reserves are analyzed quarterly. We reversed approximately $6.0 million and $14.1 million of revenue reserves during the three and nine months ended September 30, 2013, respectively, primarily consisting of Medicaid program rebates as a result of receiving claims information from certain state governments and additional data regarding the usage of CUBICIN by managed care organizations.
	International Product Revenues
	Sales with international distribution partners are based upon contractually predetermined transfer price arrangements. Once our distribution partner sells the product to a third party, we may also be owed an additional payment or royalty. Certain agreements with our distribution partners contain multiple elements in which we have continuing performance obligations. In arrangements for which we determine that the undelivered elements cannot be separated from the delivered elements, payments from distribution partners for product are recorded as deferred revenue and amortized to international product revenues over the remaining performance obligation.
Basic and Diluted Net Income (loss) Per Share	'
	Basic and Diluted Net Income (Loss) Per Share
	Basic net income (loss) per common share has been computed by dividing net income (loss) by the weighted average number of shares outstanding during the period. Diluted net income (loss) per common share has been computed by dividing diluted net income (loss) by the weighted average diluted number of shares outstanding during the period. Except where the result would be antidilutive to net income, diluted net income per common share has been computed assuming the conversion of obligations and the elimination of the interest expense related to our 2.50% convertible senior notes due 2017 (2017 Notes), 1.125% convertible senior notes due 2018 (2018 Notes), 1.875% convertible senior notes due 2020 (2020 Notes), the exercise of stock options, the exercise of warrants issued in connection with the convertible bond hedge transactions discussed below, and the vesting of restricted stock units (RSUs), as well as their related income tax effects.
	In September 2013, in connection with the issuance of the 2018 Notes and 2020 Notes, we entered into convertible bond hedge transactions. The convertible bond hedges are not considered for purposes of calculating the number of diluted shares outstanding, as their effect would be antidilutive. The convertible bond hedges are generally expected, but not guaranteed, to reduce the potential dilution upon conversion of the 2018 Notes and 2020 Notes. See Note H., "Debt," for additional information.
	The following table sets forth the computation of basic and diluted net income (loss) per common share for the periods presented:
		Three Months Ended September 30,							Nine Months Ended September 30,
		2014				2013			2014			2013
		(in thousands, except share and per share data)
	Net income (loss), basic	$	22,829			$	(33,895	)	$	71,090		$	(12,565	)
	Effect of dilutive securities:
	Interest on 2017 Notes, net of tax	772				—			2,343			—
	Debt issuance costs related to 2017 Notes, net of tax	104				—			315			—
	Debt discount amortization related to 2017 Notes, net of tax	1,100				—			3,265			—
	Net income (loss), diluted	$	24,805			$	(33,895	)	$	77,013		$	(12,565	)
	Shares used in calculating basic net income (loss) per common share	75,834,443				67,841,665			75,400,064			66,122,521
	Effect of dilutive securities:
	Options to purchase shares of common stock and RSUs	2,318,634				—			2,658,833			—
	2017 Notes convertible into shares of common stock	7,842,650				—			7,842,763			—
	Shares used in calculating diluted net income (loss) per common share	85,995,727				67,841,665			85,901,660			66,122,521
	Basic net income (loss) per common share	$	0.3			$	(0.50	)	$	0.94		$	(0.19	)
	Diluted net income (loss) per common share	$	0.29			$	(0.50	)	$	0.9		$	(0.19	)
	Potential common shares excluded from the calculation of diluted net income (loss) per common share, as their inclusion would have been antidilutive, were as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014		2013
	Options to purchase shares of common stock and RSUs	904,954			8,739,777			750,827		8,739,777
	Warrants	9,705,442			9,705,442			9,705,442		9,705,442
	2020 Notes convertible into shares of common stock	5,459,311			5,459,311			5,459,311		5,459,311
	2018 Notes convertible into shares of common stock	4,246,131			4,246,131			4,246,131		4,246,131
	2017 Notes convertible into shares of common stock	—			7,842,943			—		7,842,943
	At our annual meeting of shareholders in June 2014, our stockholders approved an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 150.0 million to 300.0 million.
Accumulated Other Comprehensive Income	'
	Accumulated Other Comprehensive Income
	Accumulated other comprehensive income consists of unrealized gains or losses on available-for-sale securities and foreign currency translation adjustments. Amounts recorded to accumulated other comprehensive income for the three and nine months ended September 30, 2014 and 2013, were not material. Additionally, there were no material reclassifications out of accumulated other comprehensive income for the three and nine months ended September 30, 2014 and 2013.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. The standard clarifies that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. Additionally, compensation cost should be recognized in the period in which it becomes probable that the performance condition will be achieved. This ASU is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. We elected to adopt this standard in the third quarter of 2014, and the adoption of this ASU did not have a material impact on our consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-09—Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification 605, Revenue Recognition. This ASU stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This ASU is effective for annual and interim reporting periods beginning on or after December 15, 2016, and early adoption is not permitted. The ASU permits the use of two transition methods, either retrospectively to each prior reporting period presented or as a cumulative-effect adjustment as of the date of adoption. We have not yet selected a transition method, and are currently evaluating the impact of the adoption of this ASU on our consolidated financial statements.

BASIS_OF_PRESENTATION_AND_ACCO2

BASIS OF PRESENTATION AND ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Concentration of risk	'
		Percentage of Total Accounts Receivable Balance as of
		September 30, 2014		December 31, 2013
	AmerisourceBergen Drug Corporation	17%		18%
	Cardinal Health, Inc.	18%		17%
	McKesson Corporation	22%		18%
		Percentage of Total Net Revenues for the Three Months Ended September 30,				Percentage of Total Net Revenues for the Nine Months Ended September 30,
		2014		2013		2014		2013
	AmerisourceBergen Drug Corporation	18%		18%		17%		19%
	Cardinal Health, Inc.	16%		17%		17%		17%
	McKesson Corporation	21%		18%		19%		18%
Schedule of gross U.S. product revenues offset by provisions	'
	Gross U.S. product revenues were offset by provisions for the three and nine months ended September 30, 2014 and 2013, as follows:
		Three Months Ended September 30,							Nine Months Ended September 30,
		2014				2013			2014			2013
		(in thousands)
	Gross U.S. product revenues	$	350,471			$	277,999		$	954,586		$	796,217
	Provisions offsetting U.S. product revenues:
	Contractual adjustments	(21,443		)		(13,249		)	(63,262		)	(43,281		)
	Governmental rebates	(37,145		)		(21,154		)	(93,724		)	(56,589		)
	Total provisions offsetting product revenues	(58,588		)		(34,403		)	(156,986		)	(99,870		)
	U.S. product revenues, net	$	291,883			$	243,596		$	797,600		$	696,347
Computation of basic and diluted net income (loss) per common share	'
	The following table sets forth the computation of basic and diluted net income (loss) per common share for the periods presented:
		Three Months Ended September 30,							Nine Months Ended September 30,
		2014				2013			2014			2013
		(in thousands, except share and per share data)
	Net income (loss), basic	$	22,829			$	(33,895	)	$	71,090		$	(12,565	)
	Effect of dilutive securities:
	Interest on 2017 Notes, net of tax	772				—			2,343			—
	Debt issuance costs related to 2017 Notes, net of tax	104				—			315			—
	Debt discount amortization related to 2017 Notes, net of tax	1,100				—			3,265			—
	Net income (loss), diluted	$	24,805			$	(33,895	)	$	77,013		$	(12,565	)
	Shares used in calculating basic net income (loss) per common share	75,834,443				67,841,665			75,400,064			66,122,521
	Effect of dilutive securities:
	Options to purchase shares of common stock and RSUs	2,318,634				—			2,658,833			—
	2017 Notes convertible into shares of common stock	7,842,650				—			7,842,763			—
	Shares used in calculating diluted net income (loss) per common share	85,995,727				67,841,665			85,901,660			66,122,521
	Basic net income (loss) per common share	$	0.3			$	(0.50	)	$	0.94		$	(0.19	)
	Diluted net income (loss) per common share	$	0.29			$	(0.50	)	$	0.9		$	(0.19	)
Potential common shares excluded from calculation of diluted net income (loss) per common share, as their inclusion would have been antidilutive	'
	Potential common shares excluded from the calculation of diluted net income (loss) per common share, as their inclusion would have been antidilutive, were as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014		2013
	Options to purchase shares of common stock and RSUs	904,954			8,739,777			750,827		8,739,777
	Warrants	9,705,442			9,705,442			9,705,442		9,705,442
	2020 Notes convertible into shares of common stock	5,459,311			5,459,311			5,459,311		5,459,311
	2018 Notes convertible into shares of common stock	4,246,131			4,246,131			4,246,131		4,246,131
	2017 Notes convertible into shares of common stock	—			7,842,943			—		7,842,943

BUSINESS_COMBINATIONS_AND_ACQU1

BUSINESS COMBINATIONS AND ACQUISITIONS (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Schedule of acquisition-date fair value of the consideration transferred	'
	The acquisition-date fair value of the consideration transferred for the Optimer and Trius acquisitions was as follows:
		Total Acquisition-Date Fair Value
		Optimer			Trius
		(in thousands)
	Cash transferred	$	569,452		$	695,710
	Contingent consideration	115,634			4,603
	Total consideration transferred	$	685,086		$	700,313
Summary of estimated fair values of the assets acquired and liabilities assumed	'
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the respective dates of acquisition, as adjusted for measurement period adjustments recorded during the three months ended September 30, 2014:
		Optimer			Trius
		24-Oct-13			11-Sep-13
		(in thousands)
	Cash	$	31,466		$	22,697
	Investments	42,067			39,513
	Inventory	32,000			—
	IPR&D	—			659,000
	DIFICID intangible asset	561,000			—
	Contract intangible asset	36,000			—
	Deferred tax assets	116,422			93,179
	Goodwill	108,360			159,440
	Other assets acquired	15,942			5,522
	Total assets acquired	943,257			979,351
	Deferred tax liabilities	(224,062		)	(248,679		)
	Other liabilities assumed	(34,109		)	(30,359		)
	Total liabilities assumed	(258,171		)	(279,038		)
	Total net assets acquired	$	685,086		$	700,313

INVESTMENTS_Tables

INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Amortized cost and estimated fair value of marketable securities, which are considered to be available-for-sale investments	'
	The following table summarizes the amortized cost and estimated fair value of our marketable securities, which are considered to be available-for-sale investments and included in short-term investments on the condensed consolidated balance sheets:
		Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
		(in thousands)
	Balance as of September 30, 2014
	Bank deposits	$	60,200	$	—	$	—		$	60,200
	U.S. Treasury securities	70,181		5		(1		)	70,185
	Corporate and municipal notes	307,919		21		(43		)	307,897
	Total	$	438,300	$	26	$	(44	)	$	438,282
	Balance as of December 31, 2013
	Bank deposits	$	40,000	$	—	$	—		$	40,000
	U.S. Treasury securities	67,648		6		(4		)	67,650
	Corporate and municipal notes	362,561		173		(36		)	362,698
	Total	$	470,209	$	179	$	(40	)	$	470,348

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Assets and liabilities measured at fair value on a recurring basis	'
	The following table sets forth our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2014:
		Level 1		Level 2			Level 3			Total
		(in thousands)
	Assets
	Cash and cash equivalents: (1)
	Corporate and municipal notes	$	—	$	1,502		$	—		$	1,502
	Short-term investments: (2)
	Bank deposits	—		60,200			—			60,200
	U.S. Treasury securities	70,185		—			—			70,185
	Corporate and municipal notes	—		307,897			—			307,897
	Total assets	$	70,185	$	369,599		$	—		$	439,784
	Liabilities
	Contingent consideration - Optimer CVRs	$	6,094	$	—		$	—		$	6,094
	Contingent consideration - other	—		—			161,360			161,360
	Total liabilities	$	6,094	$	—		$	161,360		$	167,454
	(1)         Excludes $232.2 million of cash as of September 30, 2014.
	(2)         Excludes certificates of deposit of $15.0 million recorded at cost as of September 30, 2014.
Quantitative information associated with fair value measurement of the entity's Level 3 contingent consideration	'
	The following table provides quantitative information associated with the fair value measurement of our Level 3 contingent consideration:
		Fair Value as of September 30, 2014				Unobservable Inputs
		(in thousands)		Valuation technique		Probability of success - range (weighted average)	Periods in which milestones are expected to be achieved		Discount rate
	Trius	$	5,310	Probability-adjusted discounted cash flow		4.0% - 6.5%	2016		8.00%
						-5.80%
	Adolor	46,128		Probability-adjusted discounted cash flow		25.0% - 30.0%	2018 - 2022		5.3% / 13.0%
						-27.00%
	Calixa	109,922		Probability-adjusted discounted cash flow		40.0% - 86.0%	2014 - 2018		5.30%
						-65.00%
	Total	$	161,360
Schedule of changes in the fair value of the entity's Level 3 contingent consideration	'
	Changes in the fair value of our Level 3 contingent consideration were as follows:
		Contingent Consideration
		(in thousands)
	Beginning balance as of December 31, 2013	$	154,761
	Contingent consideration expense	6,599
	Ending balance as of September 30, 2014	$	161,360
Schedule of estimated fair values of the Convertible Senior Notes	'
	The estimated fair values of the Convertible Senior Notes consisted of the following at:
		September 30, 2014		December 31, 2013
		(in thousands)
	2020 Notes	$	499,235	$	516,843
	2018 Notes	378,452		403,473
	2017 Notes	526,833		550,317
	Total estimated fair value of Convertible Senior Notes	$	1,404,520	$	1,470,633

INVENTORY_Tables

INVENTORY (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of inventory	'
	Inventory consisted of the following at:
		September 30, 2014		December 31, 2013
		(in thousands)
	Raw materials	$	31,806	$	17,904
	Work-in-process	19,249		8,104
	Finished goods	17,651		31,655
	Inventory	68,706		57,663
	Included in other assets:
	Raw materials	50,109		57,284
	Work-in-process	—		1,882
	Finished goods	1,737		—
	Total	$	120,552	$	116,829

GOODWILL_IPRD_AND_OTHER_INTANG1

GOODWILL, IPR&D AND OTHER INTANGIBLE ASSETS, NET (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of carrying value of the entity's IPR&D assets	'
	The carrying value of our IPR&D assets consisted of the following at:
		September 30, 2014				December 31, 2013
		(in thousands)
	Development and potential commercialization of:
	SIVEXTRO	$	—			$	659,000
	Bevenopran	43,400				43,400
	ZERBAXA for HABP and VABP	174,000				174,000
	ZERBAXA for cUTI and cIAI	20,000				20,000
	Total IPR&D	$	237,400			$	896,400
Schedule of other intangible assets, net	'
	Other intangible assets, net consisted of the following at:
			September 30, 2014				December 31, 2013
			(in thousands)
	Patents		$	2,627			$	2,627
	Acquired technology rights		1,451,800				788,800
	Other intangible assets, gross		1,454,427				791,427
	Less:	accumulated amortization — patents	(2,539		)		(2,493		)
		accumulated amortization — acquired technology rights	(129,506		)		(67,868		)
	Other intangible assets, net		$	1,322,382			$	721,066
Schedule of estimated aggregate amortization of intangible assets	'
	The estimated aggregate amortization of intangible assets as of September 30, 2014, for each of the five succeeding years and thereafter is as follows:
		(in thousands)
	Remainder of 2014	$	28,002
	2015	112,004
	2016	110,724
	2017	109,484
	2018	109,484
	2019 and thereafter	852,684
	Total	$	1,322,382

ACCRUED_LIABILITIES_Tables

ACCRUED LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of accrued liabilities	'
	Accrued liabilities consisted of the following at:
		September 30, 2014		December 31, 2013
		(in thousands)
	Accrued royalties	$	48,727	$	83,591
	Accrued clinical research costs	36,269		44,830
	Accrued bonus	16,313		24,540
	Accrued restructuring	2,684		19,753
	Accrued Medicaid, Medicare and commercial rebates	26,930		18,595
	Accrued benefits and incentive compensation	14,041		18,183
	Other accrued costs	22,968		35,586
	Accrued liabilities	$	167,932	$	245,078

DEBT_Tables

DEBT (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of components of the entity's Convertible Senior Notes	'
	Long-term debt, net is comprised of our Convertible Senior Notes, as follows:
		September 30, 2014			December 31, 2013
		(in thousands)
	2020 Convertible Senior Notes
	Principal amount outstanding	$	450,000		$	450,000
	Unamortized discount	(100,763		)	(111,015		)
	Net carrying amount	349,237			338,985
	2018 Convertible Senior Notes
	Principal amount outstanding	350,000			350,000
	Unamortized discount	(56,312		)	(65,733		)
	Net carrying amount	293,688			284,267
	2017 Convertible Senior Notes
	Principal amount outstanding	228,809			228,822
	Unamortized discount	(28,241		)	(34,244		)
	Net carrying amount	200,568			194,578
	Total Convertible Senior Notes
	Principal amount outstanding	1,028,809			1,028,822
	Unamortized discount	(185,316		)	(210,992		)
	Net carrying amount	$	843,493		$	817,830

EMPLOYEE_STOCK_BENEFIT_PLANS_T

EMPLOYEE STOCK BENEFIT PLANS (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of stock-based compensation expense	'
	Stock-based compensation expense recorded in the condensed consolidated statements of comprehensive income for the three and nine months ended September 30, 2014 and 2013, is as follows:
		Three Months Ended September 30,							Nine Months Ended September 30,
		2014				2013			2014			2013
		(in thousands)
	Stock-based compensation expense allocation:
	Cost of product revenues	$	341			$	120		$	610		$	374
	Research and development expense	3,116				2,816			9,835			8,583
	Selling, general and administrative expense	5,947				5,029			17,927			15,147
	Total stock-based compensation expense	9,404				7,965			28,372			24,104
	Income tax effect	(3,069		)		(2,993		)	(9,619		)	(9,058		)
	After-tax effect of stock-based compensation expense	$	6,335			$	4,972		$	18,753		$	15,046
Schedule of option activity	'
	A summary of option activity for the nine months ended September 30, 2014, is as follows:
		Number of shares				Weighted Average Exercise Price
	Outstanding as of December 31, 2013	7,478,169				$	31.61
	Granted	759,820				$	72.36
	Exercised	(1,106,320		)		$	25.47
	Canceled	(196,027		)		$	42.41
	Outstanding as of September 30, 2014	6,935,642				$	36.75
	Vested and exercisable as of September 30, 2014	4,673,781				$	29.7
	Weighted average grant-date fair value of options granted during the period	$	19.33
Schedule of RSU activity, including PRSUs	'
	A summary of RSU activity, including PRSUs, for the nine months ended September 30, 2014, is as follows:
		Number of Shares			Weighted Average Grant Date Fair Value
	Nonvested as of December 31, 2013	882,272			$	40.97
	Granted	766,260			$	70.37
	Vested	(291,563	)		$	38
	Forfeited	(80,569	)		$	52.53
	Nonvested as of September 30, 2014	1,276,400			$	58.57

RESTRUCTURING_Tables

RESTRUCTURING (Tables)	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Schedule of activity in restructuring liability included in accrued liabilities and other long-term liabilities	'
	The following table summarizes the activity within the restructuring liability included in accrued liabilities and other long-term liabilities within the condensed consolidated balance sheets:
		Employee-Related Severance			Lease Restructuring			Total
		(in thousands)
	Balance at December 31, 2013	$	19,173		$	4,495		$	23,668
	Restructuring charges	5,315			933			6,248
	Cash payments made	(23,299		)	(2,250		)	(25,549		)
	Balance at September 30, 2014	$	1,189		$	3,178		$	4,367

INCOME_TAXES_Tables

INCOME TAXES (Tables)	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of the reconciliation of the federal statutory tax rate to the effective tax rates and the related impact to the provision (benefit) for income taxes	'
	The following tables reconcile the federal statutory tax rate to the effective tax rates and the related impact to the provision (benefit) for income taxes for the three and nine months ended September 30, 2014 and 2013:
		Three Months Ended September 30, 2014					Three Months Ended September 30, 2013
		Amount			Rate		Amount			Rate
		(in thousands, except for percentages)
	Federal statutory tax rate applied to income before taxes	$	18,822		35	%	$	(13,690	)	35	%
	Differential arising from:
	State	2,425			4.5	%	(928		)	2.4	%
	Non-deductible expenses	3,537			6.6	%	2,036			(5.2	)%
	Domestic manufacturing deduction	—			—	%	(577		)	1.5	%
	Contingent consideration	1,442			2.7	%	1,823			(4.7	)%
	2013 Federal research credit	—			—	%	(6,394		)	16.3	%
	Prior year federal research credits	—			—	%	(360		)	0.9	%
	Transaction costs	—			—	%	2,739			(7.0	)%
	Non-deductible loss on extinguishment of 2017 Notes	—			—	%	9,538			(24.4	)%
	Impact of reserve for uncertain tax positions	88			0.2	%	39			(0.1	)%
	Foreign rate differential	3,989			7.4	%	(90		)	0.2	%
	Valuation allowance - foreign losses	1,252			2.3	%	—			—	%
	Other	(606		)	(1.2	)%	644			(1.6	)%
	Total	$	30,949		57.5	%	$	(5,220	)	13.3	%
		Nine Months Ended September 30, 2014					Nine Months Ended September 30, 2013
		Amount			Rate		Amount			Rate
		(in thousands, except for percentages)
	Federal statutory tax rate applied to income before taxes	$	33,612		35	%	$	(4,946	)	35	%
	Differential arising from:
	State	2,220			2.3	%	(485		)	3.4	%
	Non-deductible expenses	2,669			2.8	%	2,438			(17.3	)%
	Domestic manufacturing deduction	—			—	%	(1,386		)	9.8	%
	Contingent consideration	(20,773		)	(21.6	)%	2,241			(15.8	)%
	2013 Federal research credit	—			—	%	(7,701		)	54.5	%
	Prior year federal research credits	—			—	%	(4,401		)	31.1	%
	Transaction costs	—			—	%	2,739			(19.4	)%
	Non-deductible loss on extinguishment of 2017 Notes	—			—	%	9,538			(67.5	)%
	Impact of reserve for uncertain tax positions	257			0.3	%	(371		)	2.6	%
	Foreign rate differential	5,751			6	%	(110		)	0.8	%
	Valuation allowance - foreign losses	1,836			1.9	%	—			—	%
	Other	(629		)	(0.7	)%	878			(6.1	)%
	Total	$	24,943		26	%	$	(1,566	)	11.1	%

BASIS_OF_PRESENTATION_AND_ACCO3

BASIS OF PRESENTATION AND ACCOUNTING POLICIES (Details) (USD $)	Sep. 30, 2014
In Millions, unless otherwise specified
Prepaid expenses and other current assets	'
Restricted Cash and Cash Equivalents Items [Line Items]	'
Restricted cash included in prepaid expenses and other current assets	$1.40
Other assets	'
Restricted Cash and Cash Equivalents Items [Line Items]	'
Restricted cash included in other assets	$0.70

BASIS_OF_PRESENTATION_AND_ACCO4

BASIS OF PRESENTATION AND ACCOUNTING POLICIES (Details 2)

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Accounts receivable

Accounts receivable

Accounts receivable

Accounts receivable

Accounts receivable

Accounts receivable

Revenues

Revenues

Revenues

Revenues

Revenues

Revenues

Revenues

Revenues

Revenues

Revenues

Revenues

Revenues

AmerisourceBergen Drug Corporation

AmerisourceBergen Drug Corporation

Cardinal Health, Inc.

Cardinal Health, Inc.

McKesson Corporation

McKesson Corporation

AmerisourceBergen Drug Corporation

AmerisourceBergen Drug Corporation

AmerisourceBergen Drug Corporation

AmerisourceBergen Drug Corporation

Cardinal Health, Inc.

Cardinal Health, Inc.

Cardinal Health, Inc.

Cardinal Health, Inc.

McKesson Corporation

McKesson Corporation

McKesson Corporation

McKesson Corporation

Concentration of risk

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Benchmark percentage Concentration of risk

17.00%

18.00%

18.00%

17.00%

22.00%

18.00%

18.00%

18.00%

17.00%

19.00%

16.00%

17.00%

17.00%

17.00%

21.00%

18.00%

19.00%

18.00%

BASIS_OF_PRESENTATION_AND_ACCO5

BASIS OF PRESENTATION AND ACCOUNTING POLICIES (Details 3) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Gross U.S. product revenues offset by provisions	'	'	'	'
Gross U.S. product revenues	$350,471,000	$277,999,000	$954,586,000	$796,217,000
Provisions offsetting U.S. product revenues:	'	'	'	'
Contractual adjustments	-21,443,000	-13,249,000	-63,262,000	-43,281,000
Governmental rebates	-37,145,000	-21,154,000	-93,724,000	-56,589,000
Total provisions offsetting product revenues	-58,588,000	-34,403,000	-156,986,000	-99,870,000
U.S. product revenues, net	291,883,000	243,596,000	797,600,000	696,347,000
Reversal of revenue reserves primarily related to Medicaid program	'	$6,000,000	'	$14,100,000

BASIS_OF_PRESENTATION_AND_ACCO6

BASIS OF PRESENTATION AND ACCOUNTING POLICIES (Details 4) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Basic and diluted net income (loss) per common share	'	'	'	'
Net income (loss), basic	$22,829	($33,895)	$71,090	($12,565)
Effect of dilutive securities:	'	'	'	'
Net income (loss), diluted	24,805	-33,895	77,013	-12,565
Shares used in calculating basic net income (loss) per common share	75,834,443	67,841,665	75,400,064	66,122,521
Effect of dilutive securities:	'	'	'	'
Options to purchase shares of common stock and RSUs	2,318,634	0	2,658,833	0
Shares used in calculating diluted net income (loss) per common share	85,995,727	67,841,665	85,901,660	66,122,521
Basic net income (loss) per common share (in dollars per share)	$0.30	($0.50)	$0.94	($0.19)
Diluted net income (loss) per common share (in dollars per share)	$0.29	($0.50)	$0.90	($0.19)
2017 Notes convertible into shares of common stock	'	'	'	'
Debt instrument interest rate	'	'	'	'
Notes stated interest rate percentage	2.50%	'	2.50%	'
Effect of dilutive securities:	'	'	'	'
Interest on 2017 Notes, net of tax	772	0	2,343	0
Debt issuance costs related to 2017 Notes, net of tax	104	0	315	0
Debt discount amortization related to 2017 Notes, net of tax	$1,100	$0	$3,265	$0
Effect of dilutive securities:	'	'	'	'
2017 Notes convertible into shares of common stock	7,842,650	0	7,842,763	0
2018 Notes convertible into shares of common stock	'	'	'	'
Debt instrument interest rate	'	'	'	'
Notes stated interest rate percentage	1.13%	'	1.13%	'
2020 Notes convertible into shares of common stock	'	'	'	'
Debt instrument interest rate	'	'	'	'
Notes stated interest rate percentage	1.88%	'	1.88%	'

BASIS_OF_PRESENTATION_AND_ACCO7

BASIS OF PRESENTATION AND ACCOUNTING POLICIES (Details 5) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014	31-May-14	Dec. 31, 2013
Number of authorized shares of common stock	'	'	'	'	'	'	'
Common stock, authorized shares	300,000,000	'	300,000,000	'	300,000,000	150,000,000	150,000,000
Reclassifications from accumulated other comprehensive income	'	'	'	'	'	'	'
Reclassifications out of accumulated other comprehensive income	$0	$0	$0	$0	'	'	'
Options to purchase shares of common stock and RSUs	'	'	'	'	'	'	'
Potential common shares excluded from the calculation of diluted net income (loss) per common share	'	'	'	'	'	'	'
Antidilutive securities related to potential shares excluded from calculation of net income (loss) per share (in shares)	904,954	8,739,777	750,827	8,739,777	'	'	'
Warrants	'	'	'	'	'	'	'
Potential common shares excluded from the calculation of diluted net income (loss) per common share	'	'	'	'	'	'	'
Antidilutive securities related to potential shares excluded from calculation of net income (loss) per share (in shares)	9,705,442	9,705,442	9,705,442	9,705,442	'	'	'
2020 Notes convertible into shares of common stock	'	'	'	'	'	'	'
Potential common shares excluded from the calculation of diluted net income (loss) per common share	'	'	'	'	'	'	'
Antidilutive securities related to potential shares excluded from calculation of net income (loss) per share (in shares)	5,459,311	5,459,311	5,459,311	5,459,311	'	'	'
2018 Notes convertible into shares of common stock	'	'	'	'	'	'	'
Potential common shares excluded from the calculation of diluted net income (loss) per common share	'	'	'	'	'	'	'
Antidilutive securities related to potential shares excluded from calculation of net income (loss) per share (in shares)	4,246,131	4,246,131	4,246,131	4,246,131	'	'	'
2017 Notes convertible into shares of common stock	'	'	'	'	'	'	'
Potential common shares excluded from the calculation of diluted net income (loss) per common share	'	'	'	'	'	'	'
Antidilutive securities related to potential shares excluded from calculation of net income (loss) per share (in shares)	0	7,842,943	0	7,842,943	'	'	'

BUSINESS_COMBINATIONS_AND_ACQU2

BUSINESS COMBINATIONS AND ACQUISITIONS (Details) (USD $)	Sep. 30, 2014	Oct. 24, 2013	Sep. 30, 2014	Sep. 11, 2013
In Millions, except Per Share data, unless otherwise specified	Optimer Pharmaceuticals, Inc.	Optimer Pharmaceuticals, Inc.	Trius Therapeutics, Inc.	Trius Therapeutics, Inc.
	right	right		right
BUSINESS COMBINATIONS AND ACQUISITIONS	'	'	'	'
Percentage of issued and outstanding shares purchased	'	100.00%	'	100.00%
Tender offer purchase price of outstanding common stock of acquiree (in dollars per share)	'	$10.75	'	$13.50
Number of contingent value rights receivable by stockholders of acquiree	1	1	'	1
Maximum additional cash payment per share (in dollars per share)	'	$5	'	$2
Undiscounted contingent consideration payout	$253.90	$253.90	$108.40	$108.40

BUSINESS_COMBINATIONS_AND_ACQU3

BUSINESS COMBINATIONS AND ACQUISITIONS (Details 2) (USD $)	0 Months Ended		0 Months Ended
In Thousands, unless otherwise specified	Oct. 24, 2013	Oct. 24, 2013	Sep. 11, 2013	Sep. 11, 2013
	Optimer Pharmaceuticals, Inc.	Optimer Pharmaceuticals, Inc.	Trius Therapeutics, Inc.	Trius Therapeutics, Inc.
Total Acquisition-Date Fair Value	'	'	'	'
Cash transferred	$569,452	'	$695,710	'
Contingent consideration	'	115,634	'	4,603
Total consideration transferred	$685,086	'	$700,313	'

BUSINESS_COMBINATIONS_AND_ACQU4

BUSINESS COMBINATIONS AND ACQUISITIONS (Details 3) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Oct. 24, 2013	Oct. 24, 2013	Oct. 24, 2013	Sep. 11, 2013	Sep. 11, 2013	Sep. 11, 2013
In Thousands, unless otherwise specified			Optimer Pharmaceuticals, Inc.	Optimer Pharmaceuticals, Inc.	Optimer Pharmaceuticals, Inc.	Trius Therapeutics, Inc.	Trius Therapeutics, Inc.	Trius Therapeutics, Inc.
				DIFICID	Contract intangibles		DIFICID	Contract intangibles
Estimated fair values of the assets acquired and liabilities assumed	'	'	'	'	'	'	'	'
Cash	'	'	$31,466	'	'	$22,697	'	'
Investments	'	'	42,067	'	'	39,513	'	'
Inventory	'	'	32,000	'	'	0	'	'
IPR&D	'	'	0	'	'	659,000	'	'
Intangible asset	'	'	'	561,000	36,000	'	0	0
Deferred tax assets	'	'	116,422	'	'	93,179	'	'
Goodwill	381,930	381,930	108,360	'	'	159,440	'	'
Other assets acquired	'	'	15,942	'	'	5,522	'	'
Total assets acquired	'	'	943,257	'	'	979,351	'	'
Deferred tax liabilities	'	'	-224,062	'	'	-248,679	'	'
Other liabilities assumed	'	'	-34,109	'	'	-30,359	'	'
Total liabilities assumed	'	'	-258,171	'	'	-279,038	'	'
Total net assets acquired	'	'	$685,086	'	'	$700,313	'	'

INVESTMENTS_Details

INVESTMENTS (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Available-for-sale investments	'	'
Amortized Cost	$438,300	$470,209
Unrealized Gains	26	179
Unrealized Losses	-44	-40
Fair Value	438,282	470,348
Bank deposits	'	'
Available-for-sale investments	'	'
Amortized Cost	60,200	40,000
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	60,200	40,000
U.S. Treasury securities	'	'
Available-for-sale investments	'	'
Amortized Cost	70,181	67,648
Unrealized Gains	5	6
Unrealized Losses	-1	-4
Fair Value	70,185	67,650
Corporate and municipal notes	'	'
Available-for-sale investments	'	'
Amortized Cost	307,919	362,561
Unrealized Gains	21	173
Unrealized Losses	-43	-36
Fair Value	$307,897	$362,698

INVESTMENTS_Details_2

INVESTMENTS (Details 2) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
		Excluded portion	Excluded portion
Available-for-sale investments	'	'	'
Maximum Term of Original Maturity to Classify Instrument as Cash Equivalents	'90 days	'	'
Certificates of deposit	'	$15	$17.20

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Sep. 30, 2014		Dec. 31, 2013
Assets	'		'
Short-term investments	$438,282,000		$470,348,000
Liabilities	'		'
Contingent consideration	161,360,000		'
Excluded portion	'		'
Liabilities	'		'
Cash	232,200,000		'
Certificate of deposit excluded and recorded at cost	15,000,000		17,200,000
Optimer CVRs	'		'
Liabilities	'		'
Contingent consideration	'		68,600,000
Bank deposits	'		'
Assets	'		'
Short-term investments	60,200,000		40,000,000
U.S. Treasury securities	'		'
Assets	'		'
Short-term investments	70,185,000		67,650,000
Corporate and municipal notes	'		'
Assets	'		'
Short-term investments	307,897,000		362,698,000
Recurring Basis | Level 1	'		'
Assets	'		'
Total assets	70,185,000		'
Liabilities	'		'
Total liabilities	6,094,000		'
Recurring Basis | Level 1 | Optimer CVRs	'		'
Liabilities	'		'
Contingent consideration	6,094,000		'
Recurring Basis | Level 1 | Other	'		'
Liabilities	'		'
Contingent consideration	0		'
Recurring Basis | Level 1 | Bank deposits	'		'
Assets	'		'
Short-term investments	0	[1]	'
Recurring Basis | Level 1 | U.S. Treasury securities	'		'
Assets	'		'
Short-term investments	70,185,000	[1]	'
Recurring Basis | Level 1 | Corporate and municipal notes	'		'
Assets	'		'
Cash and cash equivalents	0	[2]	'
Short-term investments	0	[1]	'
Recurring Basis | Level 2	'		'
Assets	'		'
Total assets	369,599,000		'
Liabilities	'		'
Total liabilities	0		'
Recurring Basis | Level 2 | Optimer CVRs	'		'
Liabilities	'		'
Contingent consideration	0		'
Recurring Basis | Level 2 | Other	'		'
Liabilities	'		'
Contingent consideration	0		'
Recurring Basis | Level 2 | Bank deposits	'		'
Assets	'		'
Short-term investments	60,200,000	[1]	'
Recurring Basis | Level 2 | U.S. Treasury securities	'		'
Assets	'		'
Short-term investments	0	[1]	'
Recurring Basis | Level 2 | Corporate and municipal notes	'		'
Assets	'		'
Cash and cash equivalents	1,502,000	[2]	'
Short-term investments	307,897,000	[1]	'
Recurring Basis | Level 3	'		'
Assets	'		'
Total assets	0		'
Liabilities	'		'
Total liabilities	161,360,000		'
Recurring Basis | Level 3 | Optimer CVRs	'		'
Liabilities	'		'
Contingent consideration	0		'
Recurring Basis | Level 3 | Other	'		'
Liabilities	'		'
Contingent consideration	161,360,000		'
Recurring Basis | Level 3 | Bank deposits	'		'
Assets	'		'
Short-term investments	0	[1]	'
Recurring Basis | Level 3 | U.S. Treasury securities	'		'
Assets	'		'
Short-term investments	0	[1]	'
Recurring Basis | Level 3 | Corporate and municipal notes	'		'
Assets	'		'
Cash and cash equivalents	0	[2]	'
Short-term investments	0	[1]	'
Recurring Basis | Total Fair Value	'		'
Assets	'		'
Total assets	439,784,000		'
Liabilities	'		'
Total liabilities	167,454,000		'
Recurring Basis | Total Fair Value | Optimer CVRs	'		'
Liabilities	'		'
Contingent consideration	6,094,000		'
Recurring Basis | Total Fair Value | Other	'		'
Liabilities	'		'
Contingent consideration	161,360,000		'
Recurring Basis | Total Fair Value | Bank deposits	'		'
Assets	'		'
Short-term investments	60,200,000	[1]	'
Recurring Basis | Total Fair Value | U.S. Treasury securities	'		'
Assets	'		'
Short-term investments	70,185,000	[1]	'
Recurring Basis | Total Fair Value | Corporate and municipal notes	'		'
Assets	'		'
Cash and cash equivalents	1,502,000	[2]	'
Short-term investments	$307,897,000	[1]	'
[1]	Excludes certificates of deposit of $15.0 million recorded at cost as of September 30, 2014.
[2]	Excludes $232.2 million of cash as of September 30, 2014.

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 2) (USD $)

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Oct. 24, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 11, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2011

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals, Inc.

Trius Therapeutics, Inc.

Trius Therapeutics, Inc.

Trius Therapeutics, Inc.

Trius Therapeutics, Inc.

Trius Therapeutics, Inc.

Trius Therapeutics, Inc.

Adolor Corporation

Adolor Corporation

Adolor Corporation

Adolor Corporation

Adolor Corporation

Calixa Therapeutics Inc.

Calixa Therapeutics Inc.

Calixa Therapeutics Inc.

Calixa Therapeutics Inc.

Calixa Therapeutics Inc.

Glaxo Group Limited [Member]

Glaxo Group Limited [Member]

Level 2

Level 2

Level 2

Level 2

Level 2

Level 2

Level 2

Level 2

Level 3

Recurring Basis

Recurring Basis

Recurring Basis

right

right

right

Minimum

Maximum

Weighted Average

Minimum

Maximum

Weighted Average

Minimum

Maximum

Weighted Average

AnnualPayment

2020 Convertible Senior Notes

2020 Convertible Senior Notes

2018 Convertible Senior Notes

2018 Convertible Senior Notes

2017 Convertible Senior Notes

2017 Convertible Senior Notes

Contingent Consideration

Level 1

Level 2

Level 3

Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals, Inc.

Contingent Consideration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of transferable CVRs received by stockholders of acquiree

'

1

'

1

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Undiscounted contingent consideration, low range

'

$0

'

'

$0

'

'

'

'

'

$0

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Undiscounted contingent consideration, high range

'

253,900,000

'

253,900,000

108,400,000

'

108,400,000

'

'

'

233,800,000

'

'

'

'

180,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Level 3 Disclosures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration

161,360,000

'

68,600,000

'

5,310,000

5,000,000

'

'

'

'

46,128,000

44,200,000

'

'

'

109,922,000

105,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,094,000

0

0

Probability of success (as a percent)

'

'

'

'

'

'

'

4.00%

6.50%

5.80%

'

'

25.00%

30.00%

27.00%

'

'

40.00%

86.00%

65.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate (as a percent)

'

'

'

'

8.00%

'

'

'

'

'

'

'

5.30%

13.00%

'

5.30%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reconciliation of fair value using Level 3 inputs, liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at the beginning of the period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

154,761,000

'

'

'

Contingent consideration expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,599,000

'

'

'

Balance at the end of the period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

161,360,000

'

'

'

Other Fair Value Measurements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total estimated fair value of Convertible Senior Notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,404,520,000

1,470,633,000

499,235,000

516,843,000

378,452,000

403,473,000

526,833,000

550,317,000

'

'

'

'

Number of annual payments under termination agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate payments assumed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

22,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Net carrying amount of the total payable to Glaxo outstanding at the end of the period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$11,300,000

'

'

'

'

'

'

'

'

'

'

'

'

INVENTORY_Details

INVENTORY (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014
In Thousands, unless otherwise specified			DIFICID	ENTEREG
Inventory Disclosure [Abstract]	'	'	'	'
Raw materials	$31,806	$17,904	'	'
Work-in-process	19,249	8,104	'	'
Finished goods	17,651	31,655	'	'
Inventory	68,706	57,663	'	'
Included in other assets:	'	'	'	'
Raw materials	50,109	57,284	'	'
Work-in-process	0	1,882	'	'
Finished goods	1,737	0	'	'
Total	$120,552	$116,829	'	'
INVENTORY	'	'	'	'
Period in which inventory is expected to be sold	'	'	'1 year	'1 year

GOODWILL_IPRD_AND_OTHER_INTANG2

GOODWILL, IPR&D AND OTHER INTANGIBLE ASSETS, NET (Details) (USD $)	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Accumulated impairment losses	$0

GOODWILL_IPRD_AND_OTHER_INTANG3

GOODWILL, IPR&D AND OTHER INTANGIBLE ASSETS, NET (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Other intangible assets, net	'	'	'	'	'
Total IPR&D	$237,400,000	'	$237,400,000	'	$896,400,000
Finite-lived intangible assets	'	'	'	'	'
Other intangible assets, gross	1,454,427,000	'	1,454,427,000	'	791,427,000
Other intangible assets, net	1,322,382,000	'	1,322,382,000	'	721,066,000
Other intangible assets	'	'	'	'	'
Amortization expense	28,000,000	5,200,000	61,700,000	15,400,000	'
Estimated aggregate amortization of intangible assets	'	'	'	'	'
Remainder of 2014	28,002,000	'	28,002,000	'	'
2015	112,004,000	'	112,004,000	'	'
2016	110,724,000	'	110,724,000	'	'
2017	109,484,000	'	109,484,000	'	'
2018	109,484,000	'	109,484,000	'	'
2019 and thereafter	852,684,000	'	852,684,000	'	'
Total	1,322,382,000	'	1,322,382,000	'	721,066,000
Patents	'	'	'	'	'
Finite-lived intangible assets	'	'	'	'	'
Other intangible assets, gross	2,627,000	'	2,627,000	'	2,627,000
Less: accumulated amortization	-2,539,000	'	-2,539,000	'	-2,493,000
Acquired technology rights	'	'	'	'	'
Finite-lived intangible assets	'	'	'	'	'
Other intangible assets, gross	1,451,800,000	'	1,451,800,000	'	788,800,000
Less: accumulated amortization	-129,506,000	'	-129,506,000	'	-67,868,000
SIVEXTRO	'	'	'	'	'
Other intangible assets, net	'	'	'	'	'
Total IPR&D	0	'	0	'	659,000,000
SIVEXTRO | Acquired technology rights	'	'	'	'	'
Other intangible assets	'	'	'	'	'
Milestone payment capitalized	4,000,000	'	4,000,000	'	'
Bevenopran	'	'	'	'	'
Other intangible assets, net	'	'	'	'	'
Total IPR&D	43,400,000	'	43,400,000	'	43,400,000
ZERBAXA for HABP and VABP	'	'	'	'	'
Other intangible assets, net	'	'	'	'	'
Total IPR&D	174,000,000	'	174,000,000	'	174,000,000
ZERBAXA for cUTI and cIAI	'	'	'	'	'
Other intangible assets, net	'	'	'	'	'
Total IPR&D	$20,000,000	'	$20,000,000	'	$20,000,000

ACCRUED_LIABILITIES_Details

ACCRUED LIABILITIES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014
			Accrued Clinical Research Costs [Member]
Schedule of Accrued Liabilities [Line Items]	'	'	'
Accrued royalties	$48,727,000	$83,591,000	'
Accrued clinical research costs	36,269,000	44,830,000	'
Accrued bonus	16,313,000	24,540,000	'
Accrued restructuring	2,684,000	19,753,000	'
Accrued Medicaid, Medicare and commercial rebates	26,930,000	18,595,000	'
Accrued benefits and incentive compensation	14,041,000	18,183,000	'
Other accrued costs	22,968,000	35,586,000	'
Accrued liabilities	167,932,000	245,078,000	'
Change in estimate for accrued clinical research costs	'	'	$14,300,000

DEBT_Details

DEBT (Details) (USD $)

1 Months Ended

9 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Oct. 31, 2010

Sep. 30, 2014

Dec. 31, 2013

Oct. 31, 2010

Oct. 31, 2010

2018 Convertible Senior Notes and 2020 Convertible Senior Notes

2018 Convertible Senior Notes and 2020 Convertible Senior Notes

2018 Convertible Senior Notes and 2020 Convertible Senior Notes

2020 Convertible Senior Notes

2020 Convertible Senior Notes

2020 Convertible Senior Notes

2018 Convertible Senior Notes

2018 Convertible Senior Notes

2018 Convertible Senior Notes

2017 Convertible Senior Notes

2017 Convertible Senior Notes

2017 Convertible Senior Notes

2017 Convertible Senior Notes

2017 Convertible Senior Notes

2017 Convertible Senior Notes

note_series

Minimum

Maximum

note_series

Minimum

Maximum

D

D

Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount outstanding

'

$1,028,809,000

'

$1,028,822,000

'

'

'

$450,000,000

$450,000,000

'

'

$350,000,000

$350,000,000

'

'

$228,809,000

$228,822,000

'

'

Unamortized discount

'

-185,316,000

'

-210,992,000

'

'

'

-100,763,000

-111,015,000

'

'

-56,312,000

-65,733,000

'

'

-28,241,000

-34,244,000

'

'

Net carrying amount

'

843,493,000

'

817,830,000

'

'

'

349,237,000

338,985,000

'

'

293,688,000

284,267,000

'

'

200,568,000

194,578,000

'

'

Aggregate principal amount of notes issued

'

'

'

'

800,000,000

'

'

'

'

450,000,000

350,000,000

'

'

'

450,000,000

'

'

'

'

Number of note series

'

'

'

'

2

'

'

'

'

'

1

'

'

'

'

'

'

'

'

Net proceeds after debt issuance cost

'

'

'

'

775,600,000

'

'

'

'

'

'

'

'

'

436,000,000

'

'

'

'

Conversion rate of common stock

'

'

'

'

12.1318

'

'

'

'

'

'

'

'

'

34.2759

'

'

'

'

Conversion ratio, principal amount

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

Initial conversion price of shares (in dollars per share)

'

'

'

'

$82.43

'

'

'

'

'

'

'

'

'

$29.18

'

'

'

'

Number of days within 30 consecutive trading days in which the closing price of the entity's common stock must exceed the conversion price for the notes to be redeemable

'

'

'

'

'

20

'

'

'

'

'

'

'

'

'

'

'

20

'

Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be redeemable

'

'

'

'

'30 days

'

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

Convertibility of debt, closing price of stock test, percentage of stock price to conversion price that must be exceeded

'

'

'

'

130.00%

'

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

Number of consecutive business days immediately after any five consecutive trading day period during the note measurement period

'

'

'

'

'5 days

'

'

'

'

'

'

'

'

'

'5 days

'

'

'

'

Number of consecutive trading days before five consecutive business days during the note measurement period

'

'

'

'

'5 days

'

'

'

'

'

'

'

'

'

'5 days

'

'

'

'

Convertibility of debt, trading price of debt test, percentage of closing price of stock used in calculation

'

'

'

'

'

'

98.00%

'

'

'

'

'

'

'

'

'

'

'

98.00%

Notes stated interest rate percentage

'

'

'

'

'

'

'

1.88%

'

'

'

1.13%

'

'

'

2.50%

'

'

'

If-converted value in excess of the principal amount of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

291,500,000

'

'

'

Principal amount of the 2017 Notes converted

'

'

'

'

'

'

'

'

'

'

'

'

'

221,200,000

'

'

'

'

'

Convertible Bond Hedge

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock covered under convertible bond hedge (in shares)

9,705,442

'

9,705,442

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price (in dollars per unit)

82.43

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of convertible bond hedge

179,400,000

0

179,390,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant Transactions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock called by warrants (in shares)

9,705,442

'

9,705,442

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price (in dollars per share)

96.43

'

96.43

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of trading days over which warrants are exercisable

'80 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of warrants

$121,700,000

$0

$121,675,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

DEBT_Details_2

DEBT (Details 2) (Senior secured revolving credit facility, USD $)	1 Months Ended				9 Months Ended
	Nov. 30, 2012	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
				Maximum	Eurodollar rate	Eurodollar rate	Eurodollar rate	Base rate	Base rate	Base rate
						Minimum	Maximum		Minimum	Maximum
Credit Facility	'	'	'	'	'	'	'	'	'	'
Maximum borrowing capacity under credit facility	$150,000,000	'	'	'	'	'	'	'	'	'
Term of credit facility	'3 years	'	'	'	'	'	'	'	'	'
Additional borrowing allowed subject to pro forma compliance with financial covenants	'	'	'	150,000,000	'	'	'	'	'	'
Basis spread on variable rate (as a percent)	'	'	'	'	'	2.25%	3.00%	'	1.25%	2.00%
Outstanding credit facility	'	$0	$0	'	'	'	'	'	'	'
Variable rate basis	'	'	'	'	'Eurodollar rate	'	'	'Base rate	'	'

EMPLOYEE_STOCK_BENEFIT_PLANS_D

EMPLOYEE STOCK BENEFIT PLANS (Details)	Sep. 30, 2014
2014 Omnibus Incentive Plan	'
Summary of Stock-based Compensation Plans	'
Shares of common stock reserved for grant	4,200,000
Shares of common stock available for grant	5,347,920
2012 Equity Incentive Plan	'
Summary of Stock-based Compensation Plans	'
Shares of common stock available for grant	1,637,295
2014 Employee Stock Purchase Plan	'
Summary of Stock-based Compensation Plans	'
Shares of common stock reserved for grant	2,000,000

EMPLOYEE_STOCK_BENEFIT_PLANS_D1

EMPLOYEE STOCK BENEFIT PLANS (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Summary of Stock-based Compensation Expense	'	'	'	'
Total stock-based compensation	$9,404	$7,965	$28,372	$24,104
Income tax effect	-3,069	-2,993	-9,619	-9,058
After-tax effect of stock-based compensation expense	6,335	4,972	18,753	15,046
Cost of product revenues	'	'	'	'
Summary of Stock-based Compensation Expense	'	'	'	'
Total stock-based compensation	341	120	610	374
Research and development expense	'	'	'	'
Summary of Stock-based Compensation Expense	'	'	'	'
Total stock-based compensation	3,116	2,816	9,835	8,583
Selling, general and administrative expense	'	'	'	'
Summary of Stock-based Compensation Expense	'	'	'	'
Total stock-based compensation	$5,947	$5,029	$17,927	$15,147

EMPLOYEE_STOCK_BENEFIT_PLANS_D2

EMPLOYEE STOCK BENEFIT PLANS (Details 3) (USD $)	9 Months Ended
	Sep. 30, 2014
Stock options	'
Number of options	'
Outstanding as of beginning of the period (in shares)	7,478,169
Granted (in shares)	759,820
Exercised (in shares)	-1,106,320
Canceled (in shares)	-196,027
Outstanding as of end of the period (in shares)	6,935,642
Vested and exercisable as of end of the period (in shares)	4,673,781
Weighted Average Exercise Price	'
Outstanding as of beginning of the period (in dollars per share)	$31.61
Granted (in dollars per share)	$72.36
Exercised (in dollars per share)	$25.47
Canceled (in dollars per share)	$42.41
Outstanding as of end of the period (in dollars per share)	$36.75
Vested and exercisable as of end of the period (in dollars per share)	$29.70
Weighted average grant-date fair value of options granted during the period (in dollars per share)	$19.33
Restricted stock units	'
Number of restricted stock units	'
Nonvested as of beginning of the period (in shares)	882,272
Granted (in shares)	766,260
Vested (in shares)	-291,563
Forfeited (in shares)	-80,569
Nonvested as of end of the period (in shares)	1,276,400
Weighted Average Grant Date Fair Value	'
Nonvested stock as of beginning of the period (in dollars per share)	$40.97
Granted (in dollars per share)	$70.37
Vested (in dollars per share)	$38
Forfeited (in dollars per share)	$52.53
Nonvested stock as of end of the period (in dollars per share)	$58.57

RESTRUCTURING_Details

RESTRUCTURING (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Activity in the restructuring liability	'	'	'	'
Balance at the beginning of the period	'	'	$23,668	'
Restructuring charges	340	1,029	6,248	1,029
Cash payments made	'	'	-25,549	'
Balance at the end of the period	4,367	'	4,367	'
Employee-Related Severance	'	'	'	'
Activity in the restructuring liability	'	'	'	'
Balance at the beginning of the period	'	'	19,173	'
Restructuring charges	'	'	5,315	'
Cash payments made	'	'	-23,299	'
Balance at the end of the period	1,189	'	1,189	'
Lease Restructuring	'	'	'	'
Activity in the restructuring liability	'	'	'	'
Balance at the beginning of the period	'	'	4,495	'
Restructuring charges	'	'	933	'
Cash payments made	'	'	-2,250	'
Balance at the end of the period	$3,178	'	$3,178	'

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Effective Tax Amount	'	'	'	'
Federal statutory tax rate applied to income before taxes	$18,822	($13,690)	$33,612	($4,946)
Differential arising from:	'	'	'	'
State	2,425	-928	2,220	-485
Non-deductible expenses	3,537	2,036	2,669	2,438
Domestic manufacturing deduction	0	-577	0	-1,386
Contingent consideration	1,442	1,823	-20,773	2,241
2013 Federal research credit	0	-6,394	0	-7,701
Prior year federal research credits	0	-360	0	-4,401
Transaction costs	0	2,739	0	2,739
Non-deductible loss on extinguishment of 2017 Notes	0	9,538	0	9,538
Impact of reserve for uncertain tax positions	88	39	257	-371
Foreign rate differential	3,989	-90	5,751	-110
Valuation allowance - foreign losses	1,252	0	1,836	0
Other	-606	644	-629	878
Total	$30,949	($5,220)	$24,943	($1,566)
Federal statutory tax rate applied to income before taxes	35.00%	35.00%	35.00%	35.00%
Differential arising from:	'	'	'	'
State	4.50%	2.40%	2.30%	3.40%
Non-deductible expenses	6.60%	-5.20%	2.80%	-17.30%
Domestic manufacturing deduction	0.00%	1.50%	0.00%	9.80%
Contingent consideration	2.70%	-4.70%	-21.60%	-15.80%
2013 Federal research credit	0.00%	16.30%	0.00%	54.50%
Prior year federal research credits	0.00%	0.90%	0.00%	31.10%
Transaction costs	0.00%	-7.00%	0.00%	-19.40%
Non-deductible loss on extinguishment of 2017 Notes	0.00%	-24.40%	0.00%	-67.50%
Impact of reserve for uncertain tax positions	0.20%	-0.10%	0.30%	2.60%
Foreign rate differential	7.40%	0.20%	6.00%	0.80%
Valuation allowance - foreign losses	2.30%	0.00%	1.90%	0.00%
Other	-1.20%	-1.60%	-0.70%	-6.10%
Total	57.50%	13.30%	26.00%	11.10%

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013
	subsidiary
Income Tax Disclosure [Abstract]	'	'	'	'	'
Benefits from federal research credit	'	$6.80	$12.10	'	'
Uncertain tax positions	'	'	'	51.6	43.1
Number of foreign subsidiaries intellectual property rights transferred	1	'	'	'	'
Uncertain tax positions included in other long-term liabilities	'	'	'	18.5	'
Uncertain tax positions offset against deferred tax assets	'	'	'	33.1	'
Unrecognized tax benefits related to positions on 2011 and 2012 tax returns	'	'	'	$13.90	'

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
			Segment
Segment Reporting [Abstract]	'	'	'	'
Number of operating segments	'	'	1	'
Approximate percentage of revenues generated within the U. S.	94.00%	95.00%	92.00%	94.00%

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (Michael W. Bonney (CEO), Subsequent Event, USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Michael W. Bonney (CEO) | Subsequent Event	'
Subsequent Event [Line Items]	'
Additional stock-based compensation expense to be recorded due to equity awards modification	$11